Targeting Stress Response Pathways in Soft Tissue Sarcoma: The Role of Hypoxia and Autophagy in Tumor Survival by Nakazawa, Michael
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2015
Targeting Stress Response Pathways in Soft Tissue
Sarcoma: The Role of Hypoxia and Autophagy in
Tumor Survival
Michael Nakazawa
University of Pennsylvania, nakazawa@mail.med.upenn.edu
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Cell Biology Commons, and the Oncology Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/1908
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Nakazawa, Michael, "Targeting Stress Response Pathways in Soft Tissue Sarcoma: The Role of Hypoxia and Autophagy in Tumor
Survival" (2015). Publicly Accessible Penn Dissertations. 1908.
http://repository.upenn.edu/edissertations/1908
Targeting Stress Response Pathways in Soft Tissue Sarcoma: The Role of
Hypoxia and Autophagy in Tumor Survival
Abstract
Soft tissue sarcomas (STS) are a group of malignancies that arise from mesenchymal tissue, consisting of over
50 distinct histiologic subtypes. Unfortunately, the five-year survival rate of sarcoma patients has remained
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samples express low levels of EPAS1 (the gene encoding HIF-2α). Our results showed increased levels of the
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inhibitors in patients with the STS subtypes examined here.
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ABSTRACT 
 
TARGETING STRESS RESPONSE PATHWAYS IN SOFT TISSUE SARCOMA: THE ROLE OF 
HYPOXIA AND AUTOPHAGY IN TUMOR SURVIVAL 
Michael Sachio Nakazawa 
Dr. M. Celeste Simon 
Soft tissue sarcomas (STS) are a group of malignancies that arise from mesenchymal 
tissue, consisting of over 50 distinct histiologic subtypes. Unfortunately, the five-year 
survival rate of sarcoma patients has remained relatively unchanged, and due to the 
rarity of the disease, research and development of adequate therapeutics for STS lags 
behind other cancers. Therefore, understanding the molecular drivers of STS is 
important in developing new therapeutics, as well as discovering druggable processes 
that occur across multiple subtypes. One feature common to STS is hypoxia, or low O2 
conditions. Using molecular biology, biochemical approaches, genetically engineered 
mouse models, as well as querying publically available data sets, we determined that 
Hypoxia Inducible Factor (HIF)-2α suppresses fibrosarcoma, dedifferentiated 
liposarcoma, and undifferentiated pleomorphic sarcoma (UPS) growth in vivo. In 
addition, we found that STS patient samples express low levels of EPAS1 (the gene 
encoding HIF-2α). Our results showed increased levels of the calcium activated chloride 
channel ANO1, in HIF-2α deficient UPS tumors, which increased mTORC1 activity. 
Additionally, we determined that HIF-2α was epigenetically silenced in STS, and could 
be re-expressed with histone deacetylation inhibitor (HDACi) treatment. HDACi 
suppressed STS growth in vivo in a HIF-2α dependent manner. Moreover, we 
established that autophagy promotes fibrosarcoma and UPS survival under hypoxic and 
ischemic-like conditions. Autophagic inhibition, either with chloroquine or the more 
potent autophagy inhibitor Lys05, reduces UPS and fibrosarcoma growth in vitro and in 
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vivo. From these studies, future clinical studies are warranted to test histone deacetylase 
inhibitors and autophagy inhibitors in patients with the STS subtypes examined here.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
vi	
TABLE OF CONTENTS 
ABSTRACT	...............................................................................................................................	IV	
LIST OF TABLES	..................................................................................................................	VII	
LIST OF FIGURES	...............................................................................................................	VIII	
CHAPTER 1: INTRODUCTION	............................................................................................	1	
Part I: Soft tissue sarcoma and hypoxia: friend or foe?	......................................................................	1	
Part II. Interface between hypoxia, mTOR and calcium signaling	.....................................................	5	
Part III: Hypoxic regulation of autophagy	............................................................................................	9	
CHAPTER 2: EPIGENETIC RE-EXPRESSION OF HIF-2Α OPPOSES 
AGGRESSIVE SOFT TISSUE SARCOMA GROWTH IN VITRO AND IN VIVO	13	
Abstract	...............................................................................................................................................	13	
Introduction	.........................................................................................................................................	14	
Results	................................................................................................................................................	16	
Discussion	...........................................................................................................................................	46	
CHAPTER 3: AUTOPHAGY INHIBITION AS A THERAPEUTIC STRATEGY 
AGAINST SOFT TISSUE SARCOMAS	...........................................................................	53	
Abstract	...............................................................................................................................................	53	
Introduction:	........................................................................................................................................	54	
Results:	...............................................................................................................................................	55	
Discussion:	..........................................................................................................................................	71	
CHAPTER 4: CONCLUDING REMARKS	.......................................................................	73	
MATERIALS AND METHODS	............................................................................................	83	
BIBLIOGRAPHY:	....................................................................................................................	94	
	
	
	
vii	
LIST OF TABLES 
 
Table 1. DNA methylation across the EPAS1 locus from the Cancer Genome Atlas (TCGA) 
sarcoma samples _____________________________________________________________35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
viii	
LIST OF FIGURES 
 
Figure 1. Post-translational regulation of HIFα subunits under normoxic and hypoxic  
conditions____________________________________________________________________3 
Figure 2. The mTORC1 and mTORC2 pathway and its interaction with hypoxia______________7 
Figure 3. The autophagic pathway and its regulators__________________________________10 
Figure 4. Loss of HIF-2α promotes UPS tumor growth in vivo___________________________17 
Figure 5. Loss of HIF-2α increases UPS proliferation, without affecting migration or metastatic 
potential____________________________________________________________________18 
Figure 6. Loss of ARNT promotes UPS proliferation in vivo_____________________________20 
Figure 7. HIF-2α expression is decreased in human STS, and correlates with worse outcome in 
liposarcoma patients___________________________________________________________22 
Figure 8. Knockdown of HIF-2α increases dedifferentiated liposarcoma growth in vivo _______23 
Figure 9. HIF-2α, but not HIF-1α, knockdown increases fibrosarcoma growth in vivo_________24 
Figure 10. RNA-seq analysis of KP and KPH2 tumors show enrichment for genes involved in  
ribosomal biogenesis__________________________________________________________26 
Figure 11. KPH2 tumors demonstrate enhanced mTORC1 activity_______________________27 
Figure 12. HIF-2α knockdown increases mTORC1 activity in dedifferentiated liposarcoma tumors  
___________________________________________________________________________29 
Figure 13. ANO1 and calcium signaling is enhanced in HIF-2α deficient UPS tumors ________30 
Figure 14. ANO inhibition decreases mTORC1 and in vivo growth of KPH2 tumor cells_______32 
Figure 15. Epas1 expression is lost during sarcomagenesis, and EPAS1 expression negatively 
correlates with HDAC inhibitor sensitivity___________________________________________34 
Figure 16. Epas1 expression is increased upon HDAC inhibitor treatment in UPS and  
fibrosarcoma cell lines_________________________________________________________36 
Figure 17. The HDAC inhibitor Trichostatin A increases Epas1 expression, but sirtuin, DNA  
methyltransferase and EZH2 inhibition do not affect Epas1 expression___________________38 
	
	
ix	
Figure 18. SAHA inhibits growth in multiple STS subtypes in vitro, and inhibits UPS growth in vivo 
___________________________________________________________________________40 
Figure 19. Tumors develop resistance to SAHA mediated Epas1 re-expression in vivo_______41 
Figure 20. SAHA’s inhibition of UPS tumor growth is dependent on Epas1 re-expression in vivo  
___________________________________________________________________________42 
Figure 21. Overexpression of HIF-2α suppresses fibrosarcoma growth, and SAHA further  
increases HIF-2α levels and reduces growth________________________________________44 
Figure 22. SAHA’s inhibition of UPS tumor growth in vivo in combination with doxorubicin is  
dependent on Epas1 re-expression_______________________________________________45 
Figure 23. SAHA treatment decreases tumor proliferation in an autochthonous UPS mouse model 
___________________________________________________________________________47 
Figure 24. SAHA’s effect is dependent on HIF-2α re-expression in the autochthonous UPS  
mouse model________________________________________________________________48 
Figure 25. Proposed model of HIF-2α’s tumor suppressive function and its regulation in STS __50 
Figure 26. Fibrosarcoma and UPS cells show heightened sensitivity to the autophagy inhibitor  
chloroquine under hypoxic and ischemic-like stress___________________________________57 
Figure 27. Autophagic inhibition reduces HT-1080 proliferation, and this effect is enhanced under 
hypoxic or ischemic-like conditions in vitro__________________________________________58 
Figure 28. Stress conditions increase autophagic flux in STS cells in vitro, and pharmacologic  
inhibition effectively targets this pathway___________________________________________60 
Figure 29. ATG7 knockdown in fibrosarcoma cells decreases cell viability under hypoxic and  
ischemic-like stress____________________________________________________________61 
Figure 30. Loss of HIF-1α sensitizes STS cells to autophagic inhibition___________________63 
Figure 31. Chloroquine increases HIF-1α accumulation through increased ROS, but does not  
promote HIF-1α target gene expression____________________________________________64 
Figure 32. Chloroquine inhibits autophagy and growth of KIA tumors in vivo________________66 
Figure 33. Chloroquine inhibits KP tumor growth in vivo_______________________________67 
	
	
x	
Figure 34. Fibrosarcoma and UPS cells are highly sensitive to the autophagy inhibitor Lys05  
under hypoxic and ischemic-like stress____________________________________________69 
Figure 35. FIbrosarcoma and UPS tumor growth is inhibited by Lys05 in vivo_______________70
	 1	
CHAPTER 1: Introduction 
 
Part I: Soft tissue sarcoma and hypoxia: friend or foe?  
A. Soft tissue sarcomas and the hypoxic response 
Soft tissue sarcomas (STS) are a rare, but diverse group of malignancies that are 
believed to originate from mesenchymal tissue, such as fat, cartilage, connective tissue, 
and muscle. There are over 50 distinct histologic STS subtypes1. However, due to the 
rarity of these cancers, as well as the multitude of subtypes driven by different molecular 
and genetic alterations, research and development of adequate therapeutics for these 
diseases lags behind other cancers, and these malignancies remain relatively 
understudied2. Of these subtypes, undifferentiated pleomorphic sarcoma (UPS), 
fibrosarcoma, and dedifferentiated liposarcoma (DD-LPS) are of particular interest, as 
they are all high-grade, undifferentiated STS that together represent up to 40% of newly 
diagnosed sarcoma cases in adults3.  
Although STS are driven by different molecular mechanisms depending on their 
subtype, one feature common among many high-grade subtypes is that there are large 
areas of significant hypoxia, or low oxygen tension. This is partly due to their rapid 
proliferation and size4,5. Importantly, hypoxia in STS patient samples and mouse models 
has been associated with lower overall survival and disease-free survival5,6, and so it is 
critical to understand how hypoxic conditions affect STS development. 
Cancer cells under these hypoxic and/or ischemic conditions utilize oxygen-
sensing pathways to adapt to the stresses of the tumor microenvironment. Additionally, 
hypoxia correlates with therapeutic resistance, both to cytotoxic chemotherapeutics and 
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radiation therapy7. While various cellular pathways are used to adapt to hypoxia, the 
hypoxia inducible factors (HIFs) function as key modulators of gene regulation under 
hypoxic stress. The HIFs consist of 3 isoforms (HIF-1α, HIF-2α, and HIF-3α)8-10, with 
HIF-1α and HIF-2α being the most well-studied, and HIF-3α consisting of multiple splice 
variants11. Under hypoxia, the oxygen labile HIF-α subunits heterodimerize with the 
stable HIF-1β subunit (also known as ARNT), and in the case of HIF-1α/-2α, this 
heterodimer binds to HIF-response elements (HREs) across the genome to promote 
gene expression12,13 (Fig. 1). 
Using high-throughput approaches, several hundred genes have now been 
demonstrated to be regulated by HIF-1α, HIF-2α, or both14. Although the hypoxia 
response element recognized by both HIFα subunits is the same (RCGTG), amino-
terminal transactivation domains (N-TAD) in the subunits appear to give transcriptional 
specificity15. Recently, much attention has focused on identifying metabolic alterations 
driven by HIFs in cancer. Although the HIFs were initially thought to function primarily 
through their angiogenic and oxygen homeostatic mechanisms in cancer16, an 
increasing body of evidence has also shown the importance of HIF driven alterations of 
metabolic pathways supporting tumor growth.  
B. HIF-1α versus HIF-2α in cancer 
Although both HIF-1α and HIF-2α are activated under hypoxic conditions, and 
they can regulate a set of overlapping genes, many important HIF targets are controlled 
specifically by one isoform or the other17-19. For instance, HIF-1α promotes the 
expression of several glycolytic enzymes, such as hexokinase 1, phosphofructokinase, 
and LDHA17,20. In contrast, HIF-2α has been demonstrated to regulate tumor initiation  
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Figure 1: Post-translational regulation of HIFα subunits under normoxic and hypoxic conditions. 
Left: Under normoxic (high O2 availability) conditions, the Hypoxia Inducible Factors (HIF)-1α and HIF-2α are 
degraded. The prolyl hydroxylase (PHD) family of enzymes hydroxylate proline residues on the HIFα subunits, 
which are recognized by the E3-ubiquitin ligase Von Hippel-Lindau (VHL). This reaction requires oxygen, 
2-oxoglutarate, ascorbate, and iron (Fe2+) as cofactors. Once ubiquitinated, HIFα subunits are degrated 
through the 26S proteasome. The Factor Inhibiting HIF (FIH) hydroxylates an asparagine residue on the 
c-terminus of HIFα, which prevents HIFα from interacting with p300/CBP transcriptional co-factors. Reactive 
oxygen species (ROS) can inhibit both PHD as well as FIH function. Right: Under hypoxic (low O2 availability) 
conditions, HIFα are not hydroxylated, and can translocate to the nucleus where they bind to their constitutive-
ly expressed partner ARNT. p300/CBP serve as transcriptional co-factors. HIFα/ARNT recognize hypoxic 
response elements (HRE) across the genome, and promote the transcription of several hundred different 
genes involved in cellular processes that help the cell survive hypoxic stress (e.g. promote angiogenesis, alter 
cellular metabolism), as well as genes that are often expressed in tumor cells (e.g. promote metastasis and 
genes involved in stem cell identity). Although HIF-1α and HIF-2α both recognize the same HRE, they can 
promote the expression of different genes.   
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and proliferation through stem cell development, blood vessel remodeling, and 
angiogenesis in multiple tumor contexts18,19.  Whereas HIF-1α and HIF-2α are often pro-
tumorigenic, in specific cellular contexts they can also function to limit tumor growth. For 
example, HIF-1α has been shown to act as a tumor suppressor in renal cell carcinoma21, 
while HIF-2α inhibits lung tumor and hepatocellular carcinoma growth in vivo22,23.  
The roles of the HIFs in STS are only beginning to be understood. In UPS and 
fibrosarcoma, HIF-1α has been shown to drive metastasis through expression of 
PLOD2, modifying the collagen milieu in the extracellular matrix to enhance migration 
and metastasis24. However, the work presented here in Chapter 2 suggests HIF-2α has 
a tumor suppressive function of HIF-1α in STS, since HIF-2α opposes the growth of 
UPS, fibrosarcoma, and DD-LPS in vivo.   
C. Epigenetic regulation of HIFα 
In addition to the HIFα’s functions in cancer, the regulation of HIF expression is 
also under active investigation. The HIFα subunits are thought to be primarily regulated 
post-translationally through the prolyl-hydroxylases (PHD1, PHD2, PHD3) family of 
enzymes and the factor inhibiting HIF (FIH). These enzymes hydroxylate specific proline 
and asparagine residues on HIF-1α and HIF-2α, leading to their recognition by the E3-
ubiquitinating enzyme von-Hippel Lindau (VHL), and ultimately their degradation through 
the 26S proteasome (Fig. 1). Beyond hydroxylation, it has demonstrated that 
phosphorylation, acetylation20, and methylation25 of specific residues can affect HIF 
activity and stability as well, although the outcome of these modifications can be HIFα 
isoform dependent. 
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In the context of cancer, recent work has demonstrated that HIF expression can 
be regulated at the transcriptional level through epigenetic mechanisms. Altered 
epigenetics, or changes in gene expression not due to DNA sequence alteration26, has 
been observed in many cancers, with deregulation of the epigenome proposed as an 
important mechanism whereby tumors progress27. Epigenetic changes can occur at the 
DNA level (e.g. DNA methylation to silence gene expression), as well as at the histone 
level, where histones can be acetylated, methylated, and phosphorylated at specific 
residues28. Depending on the specific histone modification, gene expression can be 
increased (e.g. acetylation of specific histone lysines) or decreased (e.g. H3K9 
methylation)28.  
For the HIFs, epigenetic regulation of their expression is not completely 
understood in the context of cancer. For example, it has been shown that HIF-2α 
expression is repressed in differentiated kidney cells through DNA methylation by the 
enzyme DNA methyltransferase 3a29. In renal cell carcinoma, where HIF-2α has been 
demonstrated to be pro-tumorigenic30, DNA methyltransferase 3a inactivating mutations 
commonly occur, causing de-repression of EPAS129. Interestingly, in work presented 
here in chapter 2, several soft-tissue sarcomas repress EPAS1 expression through a 
separate epigenetic mechanism, histone deacetylation, suggesting not only a context 
specificity for epigenetic HIF expression or repression, but also for different epigenetic 
mechanisms depending on the cancer type. 
Part II. Interface between hypoxia, mTOR and calcium signaling 
In addition to the HIF pathway, cells maintain their metabolic homeostasis 
through independent, but closely linked molecular signaling networks. One major sensor 
of nutrient availability is the mTOR (mammalian Target of Rapamycin) pathway. In brief, 
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the mTOR pathway integrates energy and nutrient sensing inputs by the cell, and 
controls cellular growth and proliferation31. In mammals, there are two separate mTOR 
catalytic units, called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). 
Both complexes share a catalytic mTOR subunit, mLST8, DEPTOR, and Tti1/Tel2 
complex. mTORC1 also contains raptor and PRAS40, while mTORC2 has Rictor, 
mSIn1, and protor1/2 proteins (Fig. 2). When mTORC1 is activated under energy or 
nutrient replete conditions, it drives cell growth and protein synthesis through 
phosphorylation of ribosomal S6 kinase 1 (S6K1), and the eukaryotic initiation factor 4E 
binding protein (4E-BP1)31. In contrast, mTORC2 signaling, while much less understood, 
appears insensitive to nutrient conditions but does respond to growth factors. One major 
output of mTORC2 signaling is phosphorylation and activation of Akt at Ser47332, whose 
activity can ultimately lead to mTORC1 activation (Fig. 2). It is not surprising that cancer 
cells co-opt mTOR’s pro-growth pathway, either through modulating direct33 or indirect 
(e.g. p5334 or PTEN35 loss; Akt35 or Ras36 activation) regulators of the pathway.  
Numerous internal and external stresses can alter mTOR signaling in tumor cells, 
including oxygen availability. One of the first connections identified between hypoxia and 
mTOR demonstrated that andenosine monophosphate-activated protein kinase (AMPK) 
phosphorylates TSC2 and inhibits mTORC1 in response to low energy or hypoxic 
states37. Furthermore, mTORC1 was shown to promote glycolytic flux by promoting both 
the transcription and translation of HIF-1α38,39. Loss of LKB1, the upstream kinase of 
AMPK, increased HIF-1α accumulation through both increased reactive oxygen species 
as well as mTORC1 activity40. However, HIF feeds back and inhibits the mTORC1 
pathway in an AMPK independent manner, through transcribing regulation of  
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Figure 2: The mTORC1 and mTORC2 pathway and its interaction with hypoxia 
 Key activators (green) and inhibitors (red) of the mTORC1/2 pathway are shown. A diverse array of 
extracellular inputs, such as insulin, growth factors, and amino acids, can promote mTOR activity. These 
signals lead to the inactivation of the TSC1/2 complex, the upstream inhibitor of mTORC1. This signals can 
also activate mTORC2 through PIP3 and PDK1/AKT. For mTORC1, the main outputs are phosphorylated S6K1 
and phosphorylated 4E-BP1 (bottom of the figure), which leads to increased ribosomal biogenesis and cap-de-
pendent mRNA translation respectively. mTORC2 is associated with pro-survial activity, as well as modifying 
the cytoskeleton and other metabolic adaptations. Rapamycin (light green box) inhibits mTORC1 activity, but in 
certain contexts (e.g. prolonged exposure to rapamycin) can also inhibit mTORC2.
 Through HIF-1α, hypoxia can inhibit mTORC1 through REDD1 or REDD2. Additionally, hypoxia can 
lead to energy deficiency in a cell (e.g. high AMP/ATP ratio), which can inhibit mTORC1 through AMPK. Con-
versely, HIF-2α can enhance mTORC1 activity by promoting L-leucine amino acid import through the bidirec-
tional amino acid transporter SLC7A5.
 Calcium signaling can also activate mTORC1 signaling. Increased intracellular amino acids can 
activate calmodulin (CaM), which can activate mTORC1 through hVps34. Also, higher intracellular calcium 
levels can increase mTORC1 through activating CaMKII. 
Hypoxia
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DNA damage response 1 (REDD1)41. The isoform REDD2 is also hypoxically induced 
and inhibits mTORC1, however its expression is restricted to certain tissues42,43. 
Interestingly, HIF-2α affects mTORC1 in an independent manner from HIF-1α. In the 
context of VHL-deficient mouse tissue and renal cell carcinoma lines, HIF-2α promotes 
mTOR activity by driving expression of the amino acid transporter SLC7A544, which 
functions as an antiporter by effluxing L-glutamine while importing L-leucine45. One 
theory for this differential effect on mTORC1 could be due to the different kinetics of HIF-
1α versus HIF-2α stabilization. HIF-2α stabilization occurs in higher O2 over longer 
periods of hypoxia, and cells may therefore require some basal activity of mTOR to 
survive this longer-term stress. In contrast, HIF-1α is stabilized at lower O2 
concentrations but degrades more rapidly than HIF-2α, and therefore inhibiting mTOR 
short-term might be more beneficial to cell survival (Fig. 2). 
In addition to the above-mentioned inputs that regulate mTOR signaling, calcium 
availability and its downstream signaling also promote mTORC1. Amino acids are an 
important activator of mTORC1 signaling46,47. Amino acids induce a rise of intracellular 
calcium, and can trigger mTORC1 activation through calmodulin (CaM) and the lipid 
kinase hVps3448. In addition, calcium can regulate mTORC1 through Ca2+/calmodulin-
dependent protein kinase II (CaMKII). Phosphorylation of CaMKII leads to activation of 
mTORC149,50, although the specific mechanism is not well-defined (Fig. 2).   
In multiple different sarcoma subtypes, the PI3k-Akt-mTOR pathway has been 
found to be abnormally activated51. Although different alterations of the pathway occur in 
different sarcoma subtypes, such as inactivation of TSC2 in Kaposi sarcoma52 or 
increased insulin-like growth factor receptor 1 levels in Ewing’s sarcoma53, overall the 
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mTOR pathway has been found to be dysregulated in several types of sarcoma, and 
may be an important therapeutic target for these diseases54. 
Part III: Hypoxic regulation of autophagy 
 
Autophagy is a cellular process whereby cells engulf and degrade proteins, 
organelles, and cytoplasm to recycle them, providing substrates for energy production 
and to sustain cellular metabolism55,56. Under a variety of stress conditions, including 
nutrient or growth factor depravation, cytotoxic agents, and low oxygen availability57, 
cells will activate autophagy. Depending on the cell context and type of cancer, 
autophagy can either promote or inhibit tumor growth. In malignant cells, stress-induced 
autophagy appears to be protective against adverse microenvironmental stresses and 
cytotoxic therapies. However, in healthy tissues, autophagy mediates tumor suppressive 
functions by preventing the accumulation of cellular stressors such as uncoupled 
mitochondria, peroxisomes, and damaged endoplasmic reticulum58. 
Several molecular sensors are responsible for detecting and translating these 
wide varieties of homeostatic perturbations into a pro-autophagy signal. For example, 
AMPK, which responds to increases in the AMP/ATP ratio in a cell, directly 
phosphorylates ULK1, an autophagy initiation kinase59, as well as inhibiting mTOR37. 
Misfolded proteins in the endoplasmic reticulum can activate autophagy through PERK 
as well60. Another complex which activates autophagy is Vps34-p150-Beclin 1, where 
Beclin 1’s autophagic function is inhibited by the anti-apoptotic protein Bcl-261 (Fig. 3)62.  
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Figure 3: The autophagic pathway and its regulators 
 Autophagy (or macroautophagy) is a catabolic process in which double membrane vesicles called 
autophagosomes sequester and degrade organelles, proteins, and other cytoplasmic constituents in response 
to cell stress. The autophagic pathway consists of several steps, including nucleation and sequestration of a 
phagophore, formation of a autophagosome and its fusion with a lysosome to form an autolysosome. 
 Initiation and nucleation of the autophagophore begins when several proteins, including ULK1 and 
Beclin-1, which are inhibited by mTORC1 activity and BCL-2 respectively. BNIP3, a hypoxically induced 
protein, displaces Beclin 1 from BCL-2. After nucleation, several ATG proteins are involved in the conjugation 
of phosphatidylethanolamine (PE) to LC3, to form LC3-II. LC3-II is necessary for autophagic membrane expan-
sion, recognition of autophagic cargo,and the fusion of lysosomes to autophagosomes. Another hypoxically 
induced protein, BNIP3L, is involved in sequestering mitochondria to the autophagosome. p62 functions as an 
autophagy cargo receptor, which is ultimately degraded when autolysosome forms. Once the autophagosome 
has formed, it fuses with a lysosome to generate a autolysosome, leading to the degradation of the products 
inside.
 Several autophagic inhibitors exist, which can block autophagy at different steps along the pathway. 
Shown here are bafilomycin A, chloroquine, and Lys05 block the step of autophagosome and lysosome fusion. 
Hypoxia
Bafilomycin A
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AMPK
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Once the pro-autophagy signal is activated, an autophagosome is initiated, which is a 
double membrane microvesicle. After being initiated, several other proteins elongate the 
autophagosome, such as several proteins in the ATG family (e.g. ATG5, ATG7, ATG12, 
ATG16), and LC3 conjugated to PE (LC3-II), which ultimately close the autophagosome 
around the targets to be degraded. Once formed, the autophagosome can fuse to a 
lysosome, creating an autolysosome, which ultimately degrades the contents held inside 
(Fig. 3).  
Multiple chemical inhibitors of autophagy exist that block different steps along the 
autolysosome formation pathway63. One of the best-studied inhibitors is chloroquine (or 
hydroxychloroquine), which was initially clinically approved as an anti-malarial treatment. 
Chloroquine is a lysosomotropic agent, and it accumulates in acidic compartments such 
as endosomes and lysosomes. There, it prevents acidification of the endosome, which in 
turn inhibits lysosomal enzymes that require low pH to function. This effect inhibits fusion 
and degradation of the lysosome with the autophagosome, thus preventing degradation 
of the products inside. Bafilomycin A, another commonly used autophagy inhibitor, 
inhibits autophagy at a similar step in the pathway64 (Fig. 3). Additionally, more specific 
inhibitors of autophagy are under investigation (e.g. ATG7 inhibitors), but are still at the 
preclinical stage of development63. 
Although oxygen availability affects mTORC1, one of the main suppressors of 
autophagy33 as described above, it also impacts autophagy regulators directly. For 
example, BNIP3 and BNIP3L (NIX) are upregulated by HIF-1α65,66. Although these 
proteins are implicated in apoptosis, it has also been shown that they disrupt Bcl-
2:Beclin 1 complex, freeing Beclin 1 to activate autophagy in cells (Fig. 3). BNIP3 and 
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BNIP3L have also been shown to be important in autophagy-mediated mitochondrial 
degradation, also termed mitophagy. 
 In the context of sarcoma, some preliminary studies of specific subtypes 
demonstrate that autophagy plays an important role in cell survival. For instance, in a 
screen of hypoxia-regulated genes in various soft tissue sarcomas from patients, 
BNIP3L expression was found to be one of the most upregulated genes6, suggesting 
autophagy may play an important role in these tumors’ ability to survive hypoxic stress. 
In vitro studies of malignant peripheral nerve sheath tumors (MPNST) cells showed that 
when treated with histone deacetylase inhibitors (HDACi), cells survived by activating 
autophagy. Combining autophagy inhibition with HDACi promoted apoptosis in these 
MPNST cells67. In gastrointestinal stromal tumors (GIST), autophagy inhibition 
potentiated the effects of Imatinib, a tyrosine kinase inhibitor, and the combination of 
both drugs increased cell death68. However, to date the effect of autophagy inhibition 
has not been thoroughly analyzed in all subtypes of sarcoma, and clinical trials of 
autophagy inhibitors are just starting to be performed in soft tissue sarcoma patients.  
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CHAPTER 2: Epigenetic Re-expression of HIF-2α Opposes Aggressive Soft Tissue 
Sarcoma Growth In Vitro and In Vivo 
 
Sections of this chapter have been adapted from the following manuscript: “Epigenetic 
re-expression of HIF-2α Suppresses Soft Tissue Sarcoma Growth” Nakazawa, M.S., 
Eisinger-Mathason, T.S., Sadri, N., Ochocki, J.D., Gade, T.P., Amin, R.K., Simon, M.C., 
Nature Communications (Under Review). 
	
Abstract 
In soft tissue sarcomas (STS), low intratumoral O2 (hypoxia) is a poor prognostic 
indicator. HIF-1α mediates key transcriptional responses to hypoxia, and promotes STS 
metastasis; however, the role of the related HIF-2α protein is unknown. Surprisingly, we 
found that HIF-2α inhibits high-grade STS cell growth in vivo, as loss of HIF-2α 
promoted sarcoma proliferation and increased calcium and mTORC1 signaling in 
undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Most human 
STS have reduced EPAS1 (the gene encoding HIF-2α) expression relative to normal 
tissue. Many cancers, including STS, contain altered epigenetics, and our findings define 
an epigenetic mechanism whereby EPAS1 is silenced during sarcoma progression. The 
clinically approved HDAC inhibitor Vorinostat specifically increased HIF-2α, but not HIF-
1α, accumulation in multiple STS subtypes. Vorinostat inhibited STS tumor growth, an 
effect ameliorated by HIF-2α deletion, implicating HIF-2α as a novel biomarker for 
Vorinostat efficacy in STS. 
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Introduction 
Soft-tissue sarcomas (STS) are a diverse group of malignancies arising from 
mesenchymal tissues, currently classified into approximately 50 distinct histological 
subtypes1. Each year, 12,000 new cases are diagnosed in the United States, and 
roughly 4,000 succumb to this disease69,70. While recent findings have defined molecular 
mechanisms underlying sarcomagenesis and disease progression, these cancers 
remain relatively understudied due to their varied clinical and pathological etiologies, 
making effective treatment challenging2. Current therapeutic options for localized 
disease include surgical resection, frequently in combination with radiation therapy and 
chemotherapy. For metastatic or unresectable STS, cytotoxic chemotherapy remains the 
primary approach; however, response rates are only 10 to 25%71,72. Therefore, it is 
critical to identify novel therapeutics, as well as biomarkers to predict their efficacy, in 
order to help improve patient outcomes. 
Undifferentiated Pleomorphic Sarcoma (UPS), fibrosarcoma, and de-
differentiated liposarcoma (DD-LPS) are undifferentiated, high-grade sarcomas, which 
collectively represent up to 40% of newly diagnosed sarcomas in adults3. UPS is among 
the most aggressive STS subtypes in adults, with a five-year survival rate of only 24% in 
patients with metastatic disease1,73. Although UPS comprises 15% of newly diagnosed 
STS cases, its dedifferentiated phenotype suggests that it may represent a 
morphological end-point for many other sarcomas3,74. Further characterization may 
therefore provide broader insights into other aggressive STS subtypes.  
 One prominent feature of STS, including UPS, are severely hypoxic regions, a 
phenotype associated with lower overall survival rates5,75,76. Cellular adaptation to 
hypoxic stress requires coordinated changes in gene expression, many of which are 
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mediated by Hypoxia-Inducible Factor (HIF)-1α and HIF-2α12,77,78. Although HIF-1α and 
HIF-2α are stabilized under hypoxic conditions, extensive data indicate that many 
important HIF targets are controlled specifically by one isoform or the other17,18,20,21. 
Additionally, the impact of HIF-α isoform stabilization is context-dependent, as they have 
been demonstrated to promote or suppress tumor growth in different cancers21-23. 
Several HIF inhibitors have been developed for clinical intervention, and while certain 
compounds demonstrate isoform-specific inhibition79, many affect both HIF-1α and HIF-
2α equally80,81. Thus, the role of both HIF-α subunits in specific tumor contexts must be 
characterized before using either pan or isoform-specific HIF-α drugs.  
Whereas HIF-1α has recently been shown to promote metastasis in UPS and 
fibrosarcoma24, the role of HIF-2α in STS has not been established. Using a genetically 
engineered UPS mouse model that faithfully recapitulates human disease82,83, as well as 
fibrosarcoma and liposarcoma xenografts, we found that HIF-2α expression surprisingly 
suppresses tumorigenesis. Loss of HIF-2α (encoded by the EPAS1 gene) increased 
sarcoma tumor cell proliferation. Additionally, RNA-seq analysis indicated that 
Anoctamin-1 (ANO1, DOG1, TMEM16A)84, encoding a calcium-activated chloride 
channel, was expressed at elevated levels in HIF-2α deficient autochthnous UPS tumors 
relative to controls. In turn, ANO1 overexpression coincided with elevated CAMKII and 
mTORC1 signaling in these tumors. mTORC1 senses nutrient availability, and regulates 
cellular growth, biosynthetic activity, and ribosomal biogenesis85; as such, dysregulation 
of this pathway occurs in a variety of cancer types, including sarcomas86. Decreased 
EPAS1 mRNA expression (with no copy number variation) was detected in the majority 
of STS patient samples analyzed, including UPS, fibrosarcoma, and liposarcoma. These 
data suggest that EPAS1 expression is suppressed by epigenetic mechanisms in 
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multiple sarcoma subtypes. Altered epigenetics have been observed in many cancers, 
with dysregulation of the epigenome proposed as an important mechanism whereby 
tumors progress27. Of note, treatment with the chromatin modifying agent 
suberanilohydroxamic acid (SAHA, Vorinostat), a clinically approved histone deacetylase 
inhibitor (HDACi)87, significantly increased HIF-2α expression in several STS, and 
inhibited growth in a HIF-2α dependent manner.  
Results 
 
HIF-2α suppresses tumor growth in UPS 
 
To address the role of HIF-2α in soft-tissue sarcomas, we crossed the previously 
described autochthonous “KP” (LSL-KrasG12D/+; Trp53fl/fl) UPS mouse strain83 with 
Epas1fl/fl mice88 to generate “KPH2” (LSL-KrasG12D/+; Trp53fl/fl; Epas1fl/fl) animals. Hind 
limb UPS tumors are generated by injection of adenovirus expressing Cre recombinase 
(Ad-Cre) into the gastrocnemius muscle. Of note, KPH2 mice formed UPS lesions at a 
significantly elevated rate compared to KP control animals, with 50% of KP and KPH2 
strains forming tumors 56 and 47 days, respectively, after Ad-Cre injection (Fig. 4a). 
KPH2 tumors were larger than KP controls, with significantly increased mass at 7 weeks 
post-Ad-Cre injection (Fig. 4b) PCR analysis confirmed efficient Epas1 deletion in KPH2 
tumors (Fig. 4c). Both KP and KPH2 samples displayed a similar heterogeneous, 
multinucleated appearance consistent with UPS, and local muscle invasion was also 
observed, albeit more extensively in the KPH2 than KP tumors (Fig. 4d). In agreement 
with prior reports24, KP and KPH2 tumors exhibit areas of localized hypoxia, as 
demonstrated by Hypoxyprobe staining (Fig. 4e). KPH2 tumors were also more  
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Figure 4: Loss of HIF-2a promotes UPS tumor growth in vivo. a. Tumor latency of LSL-KrasG12D/+;Trp53fl/fl 
(KP, n = 16) and LSL-KrasG12D/+;Trp53fl/fl;Epas1fl/fl (KPH2, n = 19) mice, shown as days post-injection of Ad-Cre 
virus. b. Left: A cohort of KP (n = 7) and KPH2 (n = 9) mice were sacrificed 7 weeks post-Ad-cre virus injec-
tion. Representative images of the hind limb where Ad-cre was injected in each cohort are shown. Right: 
Weight of KP and KPH2 tumors at 7 weeks post-Ad-cre injection (grams). * = P < 0.05. c. Genotyping of KPH2 
tumors shows efficient Epas1 recombination. Controls include DNA derived from a KP tail (WT), muscle from a 
KPH2 mouse (2-lox), and a tumor from a LSL-KrasG12D/+;Trp53fl/fl;Epas1fl/+ (KPH2 Het. Tumor) mouse. d. Left: 
Representative H&E stains of KP and KPH2 tumors at low magnification (upper) and higher magnification 
(lower). Histopathology of these UPS tumors were similar to prior reports using the KP mouse model27. Right: 
Local muscle invasion was observed, however it was more pronounced in KPH2 than KP tumors. Scale bar = 
100 μm. e. KP and KPH2 tumors display areas of significant hypoxia, as demonstrated by immunofluores-
cence staining of Hypoxyprobe (green). CD31+ cells (red) and DAPI nuclear staining (blue) are shown. Scale 
bar = 50 μm.
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Figure 5: Loss of HIF-2a increases UPS proliferation, without affecting migration or metastatic poten-
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KPH2 tumors for cleaved caspase-3. Scale bar = 50 μm. c. Quantification of cell migration of KP and KPH2 
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proliferative than KP, as demonstrated by BrdU uptake (Fig. 5a), while apoptotic rates 
were unchanged based on cleaved Caspase-3 levels (Fig. 5b). To assess if HIF-2α loss 
affected the migration or metastatic potential of UPS, we first performed in vitro Boyden 
chamber migration experiments under normoxic and hypoxic conditions (1%) using 
tumor cells isolated from KP and KPH2 mice. Under hypoxic conditions, a similar 
number of KP and KPH2 cells migrated (Fig. 5c). We next performed an in vivo 
metastasis assay as previously described24, with KP, KPH2, and KIA (as a positive 
control) subcutaneous allografts. While 6/10 KIA mice showed metastasis in their lungs 
(indicated by arrowhead), mice with KP (0/10) or KPH2 (0/10) tumors did not have lung 
metastasis at the time of sacrifice (Fig 5d – 5e).   
Although HIF-1α and HIF-2α have unique transcriptional targets, they also 
regulate common genes in a coordinate or even opposing manner17,20,21. To rule out the 
possibility that the effects of HIF-2α deficiency in vivo were due to compensatory HIF-1α 
activity, we deleted Arnt, the obligate binding partner of both HIF-1α and HIF-2α. 
Compared to KP mice, LSL-KrasG12D/+; Trp53fl/fl; Arntfl/fl (KPA) animals generated larger 
lesions, phenocopying KPH2 tumor characteristics. Seven weeks following Ad-Cre 
injection, KPA tumors had significantly greater mass (Fig. 6a), indicating that the effects 
of HIF-2α deletion are not due to HIF-1α-mediated compensation. Together, these data 
indicate that HIF-2α suppresses UPS tumorigenesis, in contrast to HIF-1α which has no 
effect on primary tumor growth in this model24. 
Loss of HIF-2α promotes liposarcoma and fibrosarcoma tumor growth in vivo 
To determine whether HIF-2α expression was decreased in other STS subtypes, 
we first queried publicly available microarrays of human STS using Oncomine. Analysis  
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Figure 6: Loss of ARNT increases UPS proliferation in vivo a. Left: Representative images of the hind limb 
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of a dataset originally published by Barretina et. al.89 showed that EPAS1 mRNA 
expression was lower in fibrosarcoma, leiomyosarcoma, liposarcoma, and UPS 
(previously named Malignant Fibrous Histiocytoma) patient samples compared to normal 
adipose tissue (Fig. 7a). Additionally, liposarcoma and UPS tumors demonstrated 
decreased immunostaining for HIF-2α compared to normal artery and skeletal muscle 
tissue (Fig. 7b). In a separate dataset90, decreased EPAS1 mRNA expression correlated 
with worse survival in liposarcoma patients (Fig. 7c). Of note, EPAS1 levels were 
significantly lower in more aggressive liposarcoma subtypes, such as dedifferentiated 
and pleomorphic liposarcoma (Fig. 7d - 7e), and in this dataset, the bottom 50% EPAS1 
expressing cohort have a higher risk of death (relative risk of 6.67) compared to the top 
50% EPAS1 expressing cohort. Collectively, these analyses indicate EPAS1 expression 
is decreased in multiple STS subtypes, and lower EPAS1 levels correlate with poorer 
prognosis in a set of liposarcoma patients.  
To test the functional effects of HIF-2α suppression in different STS subtypes, we 
inhibited HIF-2α using two independent shRNAs in LPS246 liposarcoma cells, which 
resulted in increased xenograft volume growth and mass (Fig. 8a – 8c). Furthermore, 
HIF-2α depletion promoted growth of HT-1080 fibrosarcoma tumor xenografts in vivo 
(Fig. 9a – 9c). Importantly, HIF-1α ablation did not affect tumor growth (Fig. 9c), 
consistent with previous reports24. These results demonstrate that inhibition of HIF-2α in 
vivo accelerates growth of multiple soft-tissue sarcomas, including UPS, fibrosarcoma, 
and liposarcoma. 
Loss of HIF-2α Increases mTORC1 Signaling in Soft Tissue Sarcomas 
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Figure 7: HIF-2α expression is decreased in human STS, and correlates with worse outcome in 
liposarcoma patients a. EPAS1 mRNA expression from Oncomine analysis of the Barretina et. al. sarcoma 
patient samples dataset. Values are normalized to median-centered intensity, and shown on a log2 scale. 
Dediff. Lipo. = Dedifferentiated Liposarcoma. Myxoid/RC Lipo. = Myxoid/Round Cell Liposarcoma. Pleomprh. 
Lipo. = Pleomorphic Liposarcoma. MFH/Myxofibro. = Myxofibrosarcoma. MFH/Pleo. = Undifferentiated Pleo-
morphic Sarcoma. b. Left: IHC staining of HIF-2α was performed on a tissue array containing normal arterial 
(Large Artery) and skeletal muscle (Skel. Muscle) tissue, and liposarcoma (Lipo), alveolar rhabdomyosarcoma 
(Alv. Rhabdo), and MFH/UPS tissues. Histopathological characterization of each tissue sample is shown 
below. Right: Higher magnification of the indicated tissues in the array. Scale bar = 100 μm. c. EPAS1 mRNA 
expression of well-differentiated liposarcoma (WD-LPS, n = 52) compared to dedifferentiated liposarcoma 
(DD-LPS, n = 20) patient samples from the Gobble et. al. dataset. Values are normalized to median-centered 
intensity, and shown on a log2 scale. d. EPAS1 expression of individual tumor samples from “Low EPAS1” and 
“High EPAS1” group, with each tumor’s subtype indicated in the legend. e. EPAS1 mRNA expression of 
well-differentiated liposarcoma (WD-LPS, n = 52) compared to dedifferentiated liposarcoma (DD-LPS, n = 20) 
patient samples from the Gobble et. al. dataset. Values are normalized to median-centered intensity, and 
shown on a log2 scale.  
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Figure 8: Knockdown of HIF-2a increases dedifferentiated liposarcoma growth in vivo a. Left: Tumor 
volume of LPS246 liposarcoma xenografts with scrambled (n = 9) or HIF-2α shRNA (n = 9). Right: Immunoblot 
demonstrating HIF-2α knockdown with two independent HIF-2α shRNAs compared to scrambled (SCR) 
shRNA. ** = P < 0.01. b. Left: Weights of LPS246 xenograft tumors with scrambled shRNA (shSCR) or HIF-2α 
shRNA (shHIF-2α 2) at time of sacrifice, measured in grams. ** = P < 0.01. Right: Image of representative 
LPS246 tumors with scrambled shRNA (shSCR) or HIF-2α shRNA (shHIF-2α 2). c. Left: Tumor volume of 
LPS246 xenografts with scrambled (n = 5) or HIF-2α shRNA 1 (n = 5). HIF-2α knockdown increased LPS246 
tumor volume, although results did not reach statistical significance (p = 0.10). Right: Ratio of the indicated 
HIF-2α shRNA’s tumor weight to scrambled shRNA control (shSCR) tumor weight in each mouse.
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Figure 9: HIF-2α, but not HIF-1α, knockdown increases fibrosarcoma growth in vivo a. Left: Immunoblot 
demonstrating HIF-2α knockdown with HIF-2α shRNA (HIF-2α 1) compared to scrambled (SCR) shRNA. ** = 
P < 0.01. Right: Tumor volume of HT-1080 fibrosarcoma xenografts with scrambled (n = 5) or HIF-2α shRNA 
(HIF-2α 1) (n = 10). b. Weights of HT-1080 xenograft tumors with scrambled shRNA (shSCR) and HIF-2α 
shRNA (shHIF-2α 1) at time of sacrifice, measured in grams. * = P < 0.05. c. Tumor volume of HT-1080 xeno-
grafts with scrambled shRNA (n = 10), HIF-1α shRNA (n = 10), and HIF-2α shRNA 2 (n = 10). ** = P < 0.01. *** 
= P < 0.001.
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To define mechanism(s) whereby HIF-2α opposes sarcomagenesis using an 
unbiased approach, we performed RNA-seq analysis of KP (n=3) and KPH2 (n=4) 
tumors. By principle component analysis, KP and KPH2 tumors segregated into distinct 
populations (Fig. 10a). Gene set enrichment analysis of differentially expressed genes 
revealed a strong enrichment for those regulating RNA Polymerase I promoter opening 
and transcription in KPH2 compared to KP samples (Fig. 10b – 10c), suggesting 
increased ribosome biogenesis in the KPH2 tumors. As c-MYC and mTORC1 signaling 
promote proliferation and ribosome biogenesis in cancers85,91, we assessed whether 
either pathway was more active in KPH2 tumors compared to KP controls. KPH2 tumors 
displayed increased c-MYC protein levels, but modest increases in the expression of 
several canonical c-MYC target genes (Myc, Ccnd1, Ccdn2, Mcm5, Cdkn1a) (Fig. 11a) 
were observed (for more discussion on this matter, see below). Additionally, Ingenuity 
Pathway Analysis (IPA) did not predict c-MYC activation in KPH2 tumors (data not 
shown). In contrast, IPA predicted increased mTOR activity based on differentially 
expressed mTOR targets between KP and KPH2 tumors (Fig. 11b). The canonical 
mTORC2 target, phosphorylated AKT at serine 473, was not significantly different 
between KP and KPH2 tumors (Fig. 11c)32. However, using a Fischer’s exact test, we 
determined that KPH2 tumors had a statistically significant mTORC1 target gene 
signature, for targets predicted to be both elevated (p = 0.014) and suppressed (p = 
0.010) by mTORC192. Canonical mTORC1 signaling outputs, phosphorylated 4E-BP1 
and S6K193, were also assessed in KP and KPH2 tumors, and elevated 4E-BP1 
phosphorylation was observed in KPH2 tumors compared to KP (Fig. 11c). We 
perceived variable increases in S6K1 phosphorylation in whole KP and KPH2 UPS 
lysates, indicating that mTORC1 activity may vary in tumor subdomains. Therefore, we 
examined phosphorylated S6 staining in tumor parenchyma by IHC, and noted  
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Figure 10: RNA-seq analysis of KP and KPH2 tumors show enrichment for genes involved in ribosomal 
biogenesis. a. Principle component analysis (PCA) mapping of RNA-seq data from KP (n = 3) and KPH2 (n = 
4) tumors. b. Gene set enrichment analysis (GSEA) comparing expression data of KP “WT” and KPH2 “Hif2a” 
autochthonous UPS tumors. Significant enrichment of genes involved in RNA polymerase I transcription and 
RNA polymerase I promoter opening in KPH2 tumors compared to KP. c. List of the top gene set enrichment 
analysis (GSEA) categories elevated in KPH2 and KP tumors, with false discovery rate (FDR) < 0.1. Enrich-
ment score and nominal p-value for each category are also displayed. 
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Figure 11: KPH2 tumors demonstrate enhanced mTORC1 activity. a Top: ImmunoblotqPCR of c-Myc in KP 
and KPH2 derived UPS tumors, with Ponceau S as loading control. Bottom: qRT-PCR of several downstream 
Myc targets (Myc, Ccnd1, Ccnd2, Mcm5, Cdkn1a) showed no statistically significantly different expression 
levels in KP (n = 4) and KPH2 (n = 3) tumors. b. Ingenuity Pathway Analysis (IPA) prediction of mTOR activity 
in KPH2 versus KP tumors, based upon mRNA expression changes from RNA-seq. Shown are interactors with 
mTOR, as calculated by IPA software, predicting mTOR to be activated. Green = decreased mRNA expression 
in KPH2 tumors. Red = increased mRNA expression in KPH2 tumors. Orange = increased predicted activity. c. 
Immunoblot assessing mTORC1 and mTORC2 activity in KP and KPH2 tumors. Phosphorylated-(p) 4E-BP1 
(indicated with an *) and S6K1 were used as mTORC1 readouts, and (p)-AKT was used as an mTORC2 
readout.  d. Left: Representative images of immunohistochemical staining of phosphorylated-S6 (phospho-S6) 
on KP (n = 5) and KPH2 (n = 5) tumors. Right: quantification of phospho-S6+ cells in KP and KPH2 tumors. 10 
high powered fields per tumor were quantified. *** = P < 0.001. e. PCR of KP and KPH2 tumor derived cell 
lines demonstrating efficient floxing of the Epas1 allele in the KPH2 cell line. DNA from a KPH2 tail is shown 
as a positive control for 2-lox. f. Immunoblot of 4E-BP1 in cell lines derived from KP and KPH2 tumors. Cells 
were subjected to 1% O2 for 16 hrs (H) or grown at 21% O2 (N).  g. Proliferation of KP and KPH2 tumor 
derived under 21% O2 or 1% O2. Each line represents three independent experiments performed in duplicate. 
** = P < 0.01.
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significantly expanded areas of phosphorylated S6 in KPH2 (n = 5) compared to KP (n = 
5) sections (Fig. 11d). Phosphorylated 4E-BP1 levels were elevated in KPH2 tumor-
derived cells as compared to KP tumor-derived cells, with the expected increase in 
unphosphorylated 4E-BP1 under hypoxic growth conditions (Fig. 11e – 11f). Consistent 
with this finding, proliferation was also increased in KPH2 cells (Fig. 11g). Similar 
increases in phosphorylated 4E-BP1, S6K1 and S6 were apparent in HIF-2α knockdown 
LPS246 xenografts (Fig. 12a – 12b). Although some heterogeneity exists in tumors 
expressing or lacking HIF-2α, taken together, these data indicate that mTORC1 activity 
is increased in HIF-2α deficient sarcomas. 
To elucidate the mechanisms whereby HIF-2α alters mTORC1 activity in UPS, 
we examined the top differentially expressed genes base on RNA-seq data. Several 
targets identified were related to skeletal muscle and extracellular matrix consistent (e.g. 
Lama5, Col18a1, Dmp1), with KPH2 showing more local invasion into the adjacent 
skeletal musculature (Fig 4d, 13a). However, Ano1 (encoding TMEM16A, Anoctamin 1, 
DOG1) transcripts were significantly increased in KPH2 tumors relative to controls (Fig. 
13b). ANO1, a protein encoding a calcium activated chloride channel84, is 
overexpressed in a variety of cancers, including gastrointestinal stromal tumors (GIST), 
breast cancer, and head and neck cancers94-96.  KPH2 tumors also exhibited elevated 
ANO1 protein levels compared to KP tumors (Fig 13c), although the available antibody 
exhibited relatively weak immunoreactivity with both KP and KPH2 tumor lysates. 
ANO1 has previously been reported to promote both EGFR and CaMKIIα 
signaling in breast cancer cell lines96. While we failed to observe a consistent pattern of 
increased EGFR phosphorylation in KPH2 tumors (Fig. 13c), these tumors expressed 
higher levels of phosphorylated CaMKIIα (Fig. 13c). These data are consistent with IPA  
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Figure 12: HIF-2α knockdown increases mTORC1 activity in dedifferentiated liposarcoma tumors. a. 
Expression of 4E-BP1 and S6K1 phosphorylation in LPS246 xenografts with scrambled (SCR) or HIF-2α (H2
α) shRNA. b. Left: Representative images of phospho-S6 immunohistochemical staining on LPS246 xeno-
grafts with scrambled (SCR) (n = 5) or HIF-2α (H2α) shRNA (n = 5). 10 high powered fields per tumor were 
quantified. * = P < 0.05. 
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a
Gene Name EntrezGene ID Fold Change pvalue padj
Lama5 16776 9.942 3.50E-55 5.30E-51
Eya1 14048 20.58 2.36E-41 1.79E-37
Dmp1 13406 15.702 6.65E-30 3.36E-26
Zim1 22776 18.915 8.39E-22 3.17E-18
Col18a1 12822 6.264 1.67E-21 5.04E-18
Lrrc32 434215 0.263 2.72E-21 6.87E-18
Ano1 101772 6.208 6.61E-21 1.43E-17
Eno3 13808 6.613 3.11E-20 5.88E-17
Kcnj12 16515 17.612 1.13E-19 1.91E-16
Nova1 664883 0.111 1.81E-19 2.74E-16
Figure 13: Ano1 and calcium signaling is enhanced in HIF-2α deficient UPS tumors. a Ten most differen-
tially expressed genes from RNA-seq of KP and KPH2 tumors. Fold changes indicated are expression chang-
es in KPH2 tumors compared to KP tumors. b. qRT-PCR Validation of Ano1 mRNA expression in KP (n = 4) 
and KPH2 (n = 3) tumors used for RNA-seq. * = P < 0.05. c. Immunoblot of ANO1 and downstream targets 
p-EGFR (Y1068) and p-CaMKIIα (T268) in KP and KPH2 autochthonous tumors. d. IPA analysis of biological 
processes differentially expressed between KP (n=4) and KPH2 (n=3) tumors. Data was generated from 
mRNA changes from RNA-seq. Processes predicted by IPA analysis to be more active in KPH2 tumors are 
colored orange, processes predicted to be less active are colored blue, and those with no predictive pattern 
available are colored grey. The statistical significance of each biological process being differentially expressed 
is shown on the x-axis.   
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analyses, which predicted increased calcium signaling in KPH2 tumors (Fig. 13d). Since 
intracellular calcium and CaMKIIα have been shown to enhance mTORC1 signaling49,50, 
we hypothesized that increased mTORC1 activity in KPH2 tumors was mediated through 
ANO1 and CAMKII signaling. To test this, we serum starved KP and KPH2 tumor 
derived cells for 24 hours, and then treated with replete media plus DMSO or CaCCinh-
A01, a small molecule inhibitor of ANO1 activity96. KPH2 cells maintained higher levels 
of ANO1 compared to KP in vitro (Fig. 14a), although this phenotype is more striking in 
tumors, likely due to the normoxic cell culture conditions. As expected, CaCCinh-A01 
treatment reduced phosphorylated CaMKII levels more effectively in KPH2 compared to 
KP cells (Fig. 14b). Moreover, CaCCinh-A01 diminished mTORC1 activation (Fig. 14b), 
consistent with our findings that ANO1 is more highly expressed in KPH2 cells. In 
addition, CaCCinh-A01 treatment decreased cell proliferation more potently in KPH2 
than KP cells after 3 days of treatment (Fig. 14c). To determine if ANO1 inhibition 
diminished HIF-2α deficient sarcoma growth in vivo, Ano1 targeted shRNA were 
introduced in KP and KPH2-derived UPS cells (Fig. 14d - 14e), to generate allografts. 
Similar to our in vitro data, inhibition of ANO1 significantly reduced tumor growth in 
KPH2 but not KP allografts (Fig. 14f – 14g). Collectively, these data suggest that loss of 
HIF-2α increases ANO1 accumulation, activating CaMKII and mTORC1 signaling in UPS 
tumors and enhancing their growth (see below for further discussion). 
HDAC inhibition increases EPAS1 expression in UPS 
Having determined that HIF-2α has a tumor suppressive role in UPS and other 
STS, we examined possible mechanisms whereby HIF-2α is silenced in these lesions. 
Initially, we analyzed Epas1 expression over time in the KP tumor model. One cohort of  
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Figure 14: ANO1 inhibition decreases mTORC1 and in vivo growth in KPH2 tumor cells. a. ANO1 protein 
levels in KP and KPH2 tumor derived cells in vitro, representative of 2 independent experiments. b. Inhibition 
of ANO1 decreases mTORC1 signaling in KPH2 cells. KP and KPH2 cells were serum starved for 24hrs, then 
replete media with DMSO control or CaCCInh-A01 (10 μM) was added for 6 hours to the cells. Lysates were 
immunoblotted for p-CAMKIIα and mTORC1 readouts p-4E-BP1 and p-S6K1. c. ANO1 inhibitor’s effect on KP 
and KPH2 cell growth. Cells were treated with DMSO control or CaCCInh-A01 (10 μM) for 3 days in 21% or 
1% O2 conditions. Shown is the percentage of cells counted in the CaCCInh-A01 treated cells versus the 
respective DMSO treated control, with each bar representing 3 biological triplicates. ** = P < 0.01. d. Immuno-
blot for Ano1 in KP and KPH2-derived cell lines infected with scrambled or 2 independent Ano1 shRNAs. e. 
Ano1 expression of KP and KPH2-derived cell lines with scrambled (SCR) or Ano1 shRNAs. Ano1 shRNA 2 
had a more robust knockdown of Ano1 expression. Each bar represents two independent experiments 
performed in triplicate. f. Left: Tumor volume of KP-derived UPS allografts expressing scrambled (SCR) (n=5) 
or Ano1 shRNA (Ano1 2) (n=5). Right: Tumor volume of KPH2-derived UPS allografts expressing scrambled 
(n=5) or Ano1 shRNA (n=5). ** = P < 0.01. g. Relative average size of KP and KPH2 tumors infected with 
scrambled (SCR) or Ano1 shRNA. The scrambled shRNA average volume was normalized to 1.0 for both KP 
and KPH2 cohorts. ** = P < 0.01.
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animals was euthanized 7 weeks post Ad-cre injection (“KP early”, n = 7), and another at 
8.5 weeks post Ad-cre injection (“KP late”, n = 9). Epas1 mRNA levels in the KP late 
cohort were significantly diminished compared to KP early, with Epas1 mRNA of mouse 
skeletal muscle shown as a comparison (Fig. 15a).  Therefore, we concluded that Epas1 
expression is lost progressively over the course of sarcomagenesis. Analysis of TCGA 
sarcoma patient samples revealed that 25% of all human sarcomas have lost at least 
one copy of EPAS1, while 67% have diploid copy number at this region (Fig. 15b). As 
EPAS1 mRNA levels are consistently diminished in several STS subtypes (Fig. 7a), we 
hypothesized that EPAS1 is epigenetically silenced in a significant fraction. Using a 
publically available dataset of human sarcoma cell lines treated with various cancer 
therapeutics, we identified a significant correlation between EPAS1 mRNA abundance 
and sensitivity to the histone deacetylase inhibitor (HDACi) Vorinostat, also known as 
suberanilohydroxamic acid (SAHA) (Fig. 15c - 5d)97. In contrast, no such correlation 
existed between HIF1A expression and SAHA sensitivity in the same cell lines (Fig. 
15e). We also analyzed DNA methylation along the EPAS1 locus in the TCGA sarcoma 
dataset, and found no consistent methylation changes in the samples (Table 1). 
Together, these results suggest that HDACs specifically suppress EPAS1 in sarcoma, 
and that re-expressing EPAS1 could be a mechanism underlying HDACi’s inhibition of 
sarcoma growth.  
To test whether HDACi could activate EPAS1 expression in sarcoma, two 
independent mouse UPS cell lines, derived from KP tumors (KP230 and KP250), were 
treated with multiple SAHA concentrations (500 nM - 2 µM) in vitro. SAHA exposure 
increased Epas1 mRNA levels (Fig. 16a), an effect also observed in HT-1080 cells (Fig. 
16b). Importantly, at the highest dose tested (2 µM), SAHA treatment had no effect on  
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Figure 15: Epas1 expression is lost during sarcomagenesis, and EPAS1 expression negatively 
correlates with HDAC inhibitor sensitivity. a. Epas1 mRNA expression of tumors isolated from KP mice 7 
weeks after ad-cre injection (early) (n = 4), 8.5 weeks after ad-cre injection (late) (n = 4), and whole skeletal 
muscle from uninjected gastrocnemius mouse muscle (n = 3). b. Copy number variation (CNV) of all sarcoma 
samples in the TCGA database (n = 264) across the EPAS1 locus, grouped into diploid, copy number amplifi-
cation, and copy number loss. c. EPAS1 mRNA expression of sarcoma cell lines classified as SAHA resistant 
(9 cell lines), intermediate resistant (Interm. Resistant) (14 cell lines), and sensitive (12 cell lines) from the 
Oncomine analysis of Garnett et. al. dataset. Values are normalized to median-centered intensity, and shown 
on a log2 scale. * = P < 0.05. ** = P < 0.01. d. EPAS1 mRNA levels in each sarcoma cell line (represented in 
part c) and their sensitivity to vorinostat treatment. e. HIF1A mRNA expression of sarcoma cell lines from 
Garnett et. al. dataset. SAHA resistant = 9 cell lines. Intermediate resistant (Interm. Resistant) = 13 cell lines. 
Sensitive = 12 cell lines.  
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Table 1: DNA methylation across the EPAS1 locus from the Cancer Genome Atlas (TCGA) 
sarcoma samples. Primary solid tumors (n = 242), recurrent solid tumors (n = 2), metastatic (n = 
1), and normal solid tissue (n = 4) were analyzed, and the mean Beta-values for each group 
shown. P-values comparing tumor tissue versus normal tissue Beta-values were calculated for 
each probe using DEseq. 
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Figure 16: Epas1 expression is increased upon HDAC inhibitor treatment in UPS and fibrosarcoma cell 
lines. a. Epas1 mRNA expression of KP230 and KP250 mouse UPS cell lines treated with DMSO control or 
SAHA at the indicated drug concentrations. Each bar represents three independent experiments performed in 
triplicate. * = P < 0.05. ** = P < 0.01. b. EPAS1 and HIF1A mRNA expression of HT-1080 cells upon DMSO 
control and SAHA (2 μM) treatment. Bars represent two independent experiments performed in triplicate. * = P 
< 0.05.  c. Hif1a mRNA expression of KP230 and KP250 cells treated with DMSO control or SAHA (2 μM). 
Each bar represents three independent experiments performed in triplicate. d. Immunoblot for HIF-1α and 
HIF-2α protein in KP230 and KP250 cells treated with DMSO control or SAHA (2 μM), grown under 21% O2 or 
0.5% O2 conditions. GAPDH served as loading control. e. Serpine1 mRNA expression of KP230 and KP250 
cells treated with DMSO control or SAHA at the indicated drug concentrations. Each bar represents three 
independent experiments performed in triplicate. * = P < 0.05. ** = P < 0.01. *** = P < 0.001. f. Chromatin 
immunoprecipitation (ChIP) of KP250 cell treated with DMSO control or SAHA (2 μM), grown under 21% O2 
(N) or 0.5% O2 (H) conditions. ChIP was performed using primers designed to amplify the 500 bp fragment 
upstream of the Epas1 and Hif1a transcription start site. Histone H3 and acetylated histone H3 specific (H3Ac) 
antibodies were used for ChIP, with IgG as negative control. Input was diluted 1:100. Results are representa-
tive of two independent experiments.  
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HIF1A mRNA in UPS or HT-1080 cell lines (Fig. 16b – 16c). Consistent with these 
findings, 2µM SAHA also increased HIF-2α protein levels in both KP230 and KP250 
cells, while HIF-1α protein was unchanged (Fig. 16d). SAHA treatment also resulted in 
elevated mRNA levels of Serpine1, a HIF-2α target98, at all concentrations tested (Fig. 
16e). Chromatin immunoprecipitation (ChIP) was performed to verify that SAHA 
exposure increased the abundance of acetylated histones at the Epas1 locus. Using 
available ChIP-seq data from the UCSC genome browser, primers targeting the region 
500 bp upstream of the Epas1 transcription start site (TSS) were designed. ChIP-
seq/RNA seq analyses of EPAS1 expressing tissues indicated this region is rich in 
histone acetylation. Treatment with 2µM SAHA increased levels of acetylated histone H3 
(H3Ac) near the Epas1 TSS compared to DMSO control under normoxic (21% O2) and 
hypoxic (0.5% O2) conditions (Fig. 16f). Conversely, no increases in H3Ac at 500 bp 
upstream of the Hif1a TSS were detected. 
To rule out off-target effects of SAHA on EPAS1, we treated KP230, KP250, and 
HT-1080 cells with an independent class I/II HDACi, Trichostatin A (Fig. 17a). 
Trichostatin A increased Epas1 and Serpine1 mRNA levels, but had no effect on Hif1a 
mRNA expression. However, treatment with nicotinamide, a class III HDACs/sirtuins 
inhibitor99, did not change Epas1 or Hif1a mRNA levels in the same cell lines (Fig. 17b). 
We also investigated whether altering DNA methylation would affect EPAS1 expression, 
given that DNA methylation regulates EPAS1 in renal cell carcinoma29. However, 
treatment with 5-azacytidine, a DNA methyltransferase inhibitor100, and 3-
Deazaneplanocin A (DZNEP), a EZH2 histone methyltransferase inhibitor, failed to 
significantly increase Epas1 mRNA levels in UPS cell lines (Fig. 17c). In aggregate, 
these results indicate that HIF-2α expression is lost during UPS disease progression,  
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Figure 17: The HDAC inhibitor Trichostatin A increases Epas1 expression, but sirtuin, DNA methyl-
transferase and EZH2 inhibition do not affect Epas1 expression. a. EPAS1, HIF1A, and SERPINE1 
mRNA expression changes upon HDAC inhibitor Trichostatin A (Trich. A) treatment in KP230, KP250, and 
HT-1080 cell lines at the indicated concentrations. Bars represent two independent experiments performed in 
triplicate. DMSO served as control treatment. * = P < 0.05. ** = P < 0.01.  b. Effect of nicotinamide treatment 
(5 mM) on KP230, KP250, and HT-1080 cells on EPAS1 and HIF1A mRNA. H2O served as control treatment. 
Bars represent three independent experiments performed in triplicate. c. Epas1 mRNA levels in three inde-
pendently derived UPS cell lines after treatment with methylation inhibitor 5-azacytidine (5-AZA, 5 μM) and 
EZH2 inhibitor 3-Deazaneplanocin A (DZNEP, 5 μM). Bars represent two independent experiments performed 
in triplicate.
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and epigenetic therapeutics like SAHA specifically elevate HIF-2α, but not HIF-1α, 
levels. 
SAHA inhibits UPS allograft growth, dependent on HIF-2α re-expression 
Findings described above suggest that SAHA treatment may suppress sarcoma 
cell proliferation and tumor growth. We first tested this hypothesis by investigating 
SAHA’s ability to inhibit UPS, HT-1080, and LPS246 sarcoma cell proliferation in vitro. 
Of note, SAHA treatment significantly decreased cell growth under both normoxia and 
hypoxia (1% O2) (Fig. 18a – 18c).  
Next, we evaluated SAHA’s therapeutic efficacy against UPS allografts in vivo, 
and found that SAHA administration (50 mg/kg/day) significantly reduced tumor growth 
(Fig. 18d), and final tumor weights (Fig. 18e). Importantly, no obvious adverse effects of 
treatment were observed, and the mice maintained weight similar to DMSO treated 
controls (Fig. 18f). Surprisingly, Epas1 mRNA levels were only slightly elevated in the 
SAHA treated tumors compared to controls, although there was no change in Hif1a 
levels, as expected (Fig. 19a). We suspected that KP tumor cells developed resistance 
to SAHA, and its effect on Epas1 re-expression, over the extended course of the 
experiment (8 days). Consistent with this hypothesis, tumors from UPS bearing mice 
treated with SAHA for only 4 days displayed significantly increased Epas1 mRNA levels 
(Fig. 19b).  
As SAHA can affect multiple cellular targets and processes101, we assessed the 
specific role of HIF-2α in SAHA-mediated anti-tumor effects. Two independent shRNAs, 
one producing a partial inhibition (H2α shRNA 1), and a second more effective shRNA  
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Figure 18: SAHA inhibits growth in multiple STS subtypes in vitro, and inhibits UPS growth in vivo. a. 
Proliferation of KP230 and KP250 cells treated with DMSO or SAHA (2 μM) under 21% O2 or 1% O2. Drug 
treatment began on day 1. Each line represents three independent experiments performed in duplicate. *** = P 
< 0.001. Cell proliferation of b) HT-1080 and c) LPS246 cells treated with DMSO control or SAHA (2 μM) in 
21% O2 and 1% O2 conditions. Drug treatment began on day 1. * = P < 0.05. *** = P < 0.001. Bars represent 
biological triplicates. d. Tumor size of subcutaneous (s.c.) KP250 allografts in mice treated with DMSO control 
(n = 10) or SAHA (50 mg/kg/day) (n = 10). Mice were treated 10 days post-injection, once tumors reached 
~100 mm3. * = P < 0.05. *** = P < 0.001. e. Weights of tumors from DMSO treated and SAHA treated mice. 
Images are representative of tumors from the DMSO and SAHA cohorts. *** = P < 0.001. f. Weights of mice 
pre-treatment and at time of sacrifice. Black squares = DMSO treated mice. Red circles = SAHA treated mice.
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Figure 19: Tumors develop resistance to SAHA mediated Epas1 re-expression in vivo. a. Epas1 and 
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(H2α shRNA 2), were used to deplete HIF-2α in KP250 cells (Fig. 20a). Both HIF-2α 
shRNAs inhibited SAHA-induced Epas1 and Serpine1 mRNA re-expression in UPS cells 
(Fig. 20b). Mice bearing in vivo UPS allografts expressing control or HIF-2α shRNAs 
were then treated with DMSO or SAHA (50 mg/kg/day) once tumors had reached 100 
mm3 (10 days post-implantation). SAHA significantly slowed the growth of control 
tumors, while HIF-2α inhibition abrogated this effect in a dose-dependent manner (Fig. 
20a). Conversely, overexpression of HIF-2α in HT-1080 fibrosarcoma cells inhibited cell 
proliferation in vitro under hypoxic conditions (Fig. 21a – 21b). When treated with SAHA, 
we observed a further increase of HIF-2α mRNA and protein expression in empty vector 
and HIF-2α overexpression cells, and a further decrease in cell proliferation likely due to 
increased expression of the endogenous HIF-2α mRNA (Fig. 21c). 
The standard chemotherapeutic approach for unresectable STS is doxorubicin71. 
In order to demonstrate that SAHA treatment could be safely and effectively 
incorporated into the clinical setting, we investigated the efficacy of combining 
doxorubicin and SAHA. Although combination therapy reduced UPS allograft growth in 
vivo compared to DMSO or doxorubicin alone (Fig. 22a), this inhibition was similar to 
SAHA treatment alone (Fig 20a). Moreover, HIF-2α inhibition in these allografts fully 
abrogated this effect. (Fig. 22b – 22c).  Collectively, these data strongly suggest that 
SAHA limits UPS proliferation in vitro and in vivo, in a HIF-2α dependent manner. 
HIF-2α expression is required for SAHA’s efficacy in an autochthonous UPS model 
We next evaluated the efficacy of SAHA in an autochthonous STS tumor model, 
using KP mice. After initiating tumors with Ad-Cre injection, we performed bi-weekly CT  
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scans of the animals’ lower limbs. When tumors reached 50-100 mm3, animals were 
treated with DMSO or SAHA (50 mg/kg) daily (Fig. 23a). SAHA decreased relative tumor 
growth over time, compared to controls (Fig. 23b), resulting in significantly reduced 
relative tumor size by day 10. (Fig. 23c). Total animal weight did not change due to 
SAHA treatment (Fig. 23d). Importantly, HIF-2α protein levels increased in SAHA-
treated tumors compared to controls (Fig. 23e). SAHA also decreased KP tumor cell 
proliferation, as indicated by reduced Ki67 staining (Fig. 23f) with no concomitant 
change in apoptosis, as shown by cleaved Caspase-3 immunohistochemical staining 
(Fig. 23g). Importantly, SAHA’s effects on tumor growth (Fig. 24a – 24b) and 
proliferation (Fig. 24c – 24d) were completely abrogated in KPH2 tumors, underscoring 
the importance of HIF-2α in SAHA-mediated anti-tumor effects. 
Discussion 
 
Current chemotherapeutic approaches for the treatment of unresectable and 
metastatic soft-tissue sarcomas have low response rates71,72. One major obstacle to 
developing better treatment regimens has been the myriad of unique subtypes with 
distinct genetic alterations2,70, coupled with the relatively low incidence of these 
malignancies. Until recently, clinical trials often combine patients with diverse STS 
histologic subtypes, which are induced by heterogeneous genetic alterations potentially 
from multiple cells of origin, into a single study. Our growing understanding of context 
specificity in tumors, particularly in sarcomas, has shown that this approach has many 
drawbacks. Newer targeted therapies are increasingly being investigated, not only in a 
sub-type specific manner, but also based on the molecular underpinning of the 
tumors102. It will be very beneficial to identify therapeutic biomarkers that span multiple 
subtypes and determine treatment strategies based on gene expression changes that  
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Figure 23: SAHA treatment decreases tumor proliferation in an autochthonous UPS mouse model. a. 
Top: Schematic of tracking autochthonous KP tumor growth in DMSO and SAHA treated mice. After Ad-Cre 
injection, mice were imaged bi-weekly until tumors were detectable and measured ~50-100 mm3. Mice were 
randomized to DMSO control (n = 5) or SAHA (n = 5) (50 mg/kg/day) treatments, and tumor growth was 
followed by bi-weekly CT scans. Bottom: Representative axial CT images of KP mice pre- and post-treatment 
with DMSO or SAHA. Dashed white line demarcates the tumor boundary. b. Relative sizes of individual tumors 
from KP mice receiving DMSO or SAHA treatment. c. Comparison of the relative sizes of all DMSO and SAHA 
treated KP tumors at sacrifice. * = P < 0.05. d. Weights of KP mice pre-treatment and at time of sacrifice. Black 
squares = DMSO treated mice. Red circles = SAHA treated mice. e. Immunoblot of HIF-2α protein in KP 
autochthonous tumors from DMSO and SAHA treated mice. GAPDH served as loading control. f) - g) Immuno-
histochemical staining of autochthonous KP tumors treated with DMSO (n = 5) or SAHA (50 mg/kg/day, n = 5). 
f) Representative images of Ki67 stained tumor sections (left), and quantification of the percentage of Ki67+ 
cells per high-powered field in DMSO treated or SAHA treated tumors (right). g) Representative images of 
cleaved caspase-3 (CC3) stained tumor sections (left), and quantification of the percentage of CC3+ cells in 
DMSO treated or SAHA treated tumors (right). ** = P < 0.01. Scale bars = 50 μM  
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Figure 24: SAHA’s effect is dependent on HIF-2α re-expression in the autochthonous UPS mouse 
model. a. Left: Representative transverse CT images of KPH2 mice pre- and post-treatment with DMSO or 
SAHA. Mice were treated and imaged as described in Fig. 23a. Right: Relative sizes of individual tumors from 
KPH2 mice receiving DMSO (n = 4) or SAHA (n = 5) treatment. b. Comparison of the relative sizes of all 
DMSO and SAHA treated KPH2 tumors at sacrifice.  c) - d) Immunohistochemical staining of autochthonous 
KPH2 tumors treated with DMSO (n = 4) or SAHA (50 mg/kg/day, n = 5). Representative images of c) Ki67 
and d) cleaved caspase-3 (CC3) stained tumors sections, with quantification of percentage of Ki67+ and 
CC3+ cells per high power field. Scale bars = 50 μM. 
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are linked to drug sensitivity. Identification of biomarkers that predict drug response 
should allow clinicians to better select patient populations most likely to respond to 
treatment2. Although these biomarkers are scarce in STS, we report here that HIF-2α 
expression levels may be particularly effective for this purpose.    
Clinical data have identified intratumoral hypoxia and HIF-1α as one of the most 
important prognostic factors in metastatic potential of STS103,104. Consistent with this 
finding, we have shown previously that HIF-1α enhances tumor metastasis through 
modifications of the collagen network in UPS and fibrosarcoma24. Conversely, we 
demonstrate here that HIF-2α expression opposes UPS, fibrosarcoma, and liposarcoma 
growth in vivo, decreasing tumor cell proliferation and inhibiting mTORC1 activity.  
Although tumors exhibit significant heterogeneity in our in vivo models, both within a 
given sample and between samples, we saw significant enrichment of mTORC1 
activation. Importantly, further work is necessary to determine if this mechanism is 
shared in other STS subtypes not examined here. It is noteworthy that low HIF-2α 
expression is correlated with lower overall survival rate in a cohort of liposarcoma 
patients90. Additionally, loss of HIF-2α did not alter metastatic potential in UPS in vitro or 
in vivo. Although mTORC2 signaling has been shown to promote HIF-2α accumulation in 
cancers like renal cell carcinoma105, our results suggest that HIF-2α inhibits mTORC1 
signaling in at least the high-grade STS subtypes examined. This context dependency of 
HIFs and mTOR signaling in cancer warrants further study. For UPS tumors, loss of HIF-
2α increases ANO1, promoting CaMKII and mTORC1 activity (Fig. 25a). Interestingly, a 
previous study demonstrated that HIF-1α inhibition increased ANO1 mRNA expression 
in renal cysts106, yet we are the first to connect HIF-2α loss with increased ANO1 in UPS.  
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Figure 25: Proposed model of HIF-2α’s tumor suppressive function and its regulation in STS  a. Model 
of EPAS1 regulation in the soft-tissue sarcomas examined. EPAS1 expression is epigenetically downregulated 
through class I/II HDACs. Loss of HIF-2α increases ANO1 and calcium signaling, which subsequently increas-
es mTORC1 activity in tumors and promotes sarcoma proliferation. HIF-2α loss may also increase sarcoma 
growth independent of this pathway. 
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However, HIF-2α may also inhibit sarcoma growth in an ANO1 and mTORC1-
independent fashion (Fig 25a). Given the multitude of targets and biological processes 
HIF-2α controls, the mechanism whereby HIF-2α inhibition increases ANO1 levels 
remains to be elucidated. Importantly, ChIP-seq data assembled in the UCSC genome 
browser show Myc/Max binding near the promoter region of ANO1 in breast and 
leukemia cells. Thus, one possible explanation for our findings is that Myc, whose levels 
are elevated in KPH2 tumors (Fig 11a), binds to the ANO1 promoter and increases 
ANO1 expression. c-MYC stimulation (or repression) of individual target genes can be 
modest107, and additional factors are required to regulate many c-MYC driven targets91.  
While the canonical c-MYC target genes we examined were slightly elevated in KPH2 
tumors, Ano1 expression was significantly increased, suggesting other input(s) are likely 
influencing its transcription. Clarifying the specific mechanism of HIF-2α mediated ANO1 
regulation will be an important topic of future studies.    
 Observations that HIF-1α and HIF-2α can play different and often opposing roles 
in various malignancies is important as HIF inhibitors are systematically being developed 
as cancer therapies20. For example, HIF-2α in clear-cell renal cell carcinoma promotes 
tumorigenesis21,30, whereas it suppresses tumorigenesis in hepatocellular carcinoma and 
non-small cell lung adenocarcinoma22,23. Although HIF-α subunit specific inhibitors are 
currently under investigation79, pan-HIFα inhibitors are also being assessed80,81. Our 
results with ARNT knockout KP mice caution against the use of pan-HIFα inhibitors for 
the treatment of STS and potentially for other tumors as well. 
 Given that HIF-2α expression opposes STS tumorigenesis, we sought a class of 
compounds that could induce re-expression of HIF-2α in sarcoma cells, and found that 
the FDA-approved histone deacetylase inhibitor (HDACi) SAHA (Vorinostat) reactivates 
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EPAS1 expression in STS cells, inhibiting sarcoma progression (Fig 25a). HDACi have 
been assessed in vitro and in vivo pre-clinically for the treatment of a variety of 
malignancies, including specific sarcoma subtypes such as malignant peripheral nerve 
sheath tumors67 and synovial sarcoma, with some early success108-110. Clinical trials 
testing chemotherapy with HDACi in STS are still ongoing, as well as newer generations 
of HDACi, such as abexinostat, with potentially improved anti-tumor effects and 
pharmokinetics111. To our knowledge this study is the first to show HDACi treatment 
reduces growth of autochthonous UPS tumors in vivo, and demonstrate that HIF-2α re-
expression is required for SAHA’s anti-proliferative effects in the context of UPS.  
Importantly, combination of standard doxorubicin, a first-line chemotherapeutic 
against STS, with SAHA could be a suitable treatment strategy that has exciting clinical 
potential. These results suggest that HDACi therapies will be most effective against 
sarcomas that have epigenetically suppressed HIF-2α expression, and not genomic 
deletion of the locus. HIF-2α may therefore serve as an important biomarker for 
clinicians designing future clinical trials with HDAC inhibitors in sarcoma patients. 
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Chapter 3: Autophagy Inhibition as a Therapeutic Strategy Against Soft Tissue 
Sarcomas  
 
Sections of this chapter have been adapted from the following manuscript: “Autophagic Inhibition 
as a Therapeutic Strategy For Soft Tissue Sarcomas” Nakazawa, M.S., Amin, R.K., Azzam, A, 
Campbell, S.L., McLellan, R., Simon, M.C. Autophagy (In Preparation). 
 
Abstract 
 
	 Autophagy is a lysosomal dependent process that helps cells survive under 
stressful growth conditions. Soft tissue sarcomas (STS) frequently contain areas of 
hypoxia (low O2), which correlates with worse survival in patients. Hypoxia can promote 
autophagy in cancers through stabilization and activation of the Hypoxia Inducible 
Factors (HIFs). However, the role of hypoxia and autophagy in STS survival remains to 
be fully elucidated. In this study, we demonstrate that hypoxic and ischemic-like stress 
increases autophagic flux in fibrosarcoma and undifferentiated pleomorphic sarcoma 
(UPS) cells, rendering them more sensitive to autophagy inhibition. In addition, loss of 
HIF-1α in STS sensitized cells to the autophagic inhibitor chloroquine. Pharmacologic 
inhibition of autophagy with chloroquine as a monotherapeutic significantly reduced 
growth of UPS tumors in vivo. Furthermore, mice treated with Lys05, a more potent 
autophagy inhibitor than chloroquine, significantly slowed tumor growth in vivo in 
fibrosarcoma and UPS tumors. 	
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Introduction:  
	
Autophagy is a cellular process whereby proteins, organelles, and cytoplasm are 
engulfed in autophagic vesicles and subsequently degraded112, in order to provide 
substrates to maintain energy production and sustain cellular metabolism55,56. Under 
stress conditions, activation of autophagy can promote cell survival. In particular, 
autophagy in transformed tumor cells promotes survival by reducing metabolic and 
cytotoxic therapy induced stress113,114.  
As solid tumors outgrow their native blood supply, they develop areas of hypoxia, 
or low O2 conditions12, which promotes autophagy33. One of the main sensors of hypoxia 
is a set of transcription factors called the hypoxia inducible factors (HIFs), which 
modulate gene expression under hypoxic stress12. Under hypoxia, the oxygen labile HIF-
1α and HIF-2α subunits heterodimerize with the constitutively stable HIF-1β subunit 
(also known as ARNT), and bind to HIF-response elements (HREs) on the genome to 
promote gene expression12,13. Although oxygen availability affects mTORC1, one of the 
main suppressors of autophagy33, it also impacts autophagy regulators directly. For 
example, HIF-1α upregulates BNIP3 and BNIP3L expression, which can induce 
autophagy and mitophagy (mitochondrial clearance) respectively65,66.  
 Soft tissue sarcomas (STS) are a rare group of malignancies that arise from 
mesenchymal tissue1, and frequently contain areas of significant hypoxia4,103. Hypoxia in 
STS has been correlated with worse outcomes5, and in high-grade fibrosarcoma and 
undifferentiated pleomorphic sarcoma (UPS) subtypes, HIF-1α has been demonstrated 
to promote metastasis24. Furthermore, hypoxia has also been associated with resistance 
to therapy in solid tumor types7. In a screen of hypoxically-regulated genes in STS from 
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patients, BNIP3L expression was found to be one of the most upregulated genes, 
suggesting that autophagy plays a role in these tumors’ survival under hypoxia6. Indeed, 
preclinical studies have shown that autophagy can promote cell survival of certain STS 
subtypes, such as malignant peripheral nerve sheath tumors (MPNST)67 and 
gastrointestinal stromal tumors68. However, the role of autophagy and hypoxia in 
fibrosarcoma and UPS remains unclear. We demonstrate here that in both fibrosarcoma 
and UPS cells, pharmacologic inhibition of autophagy with chloroquine or bafilomycin A 
suppresses growth, and under hypoxic and ischemic-like conditions, they show 
enhanced sensitivity to these therapeutics. Loss of HIF-1α in STS further sensitizes cells 
to autophagic inhibition in vitro. In vivo, chloroquine administration reduced tumor burden 
in fibrosarcoma xenografts and UPS allografts. Furthermore, Lys05, a bivalent 
aminoquinoline autophagy inhibitor that is more potent than chloroquine115, reduced 
tumor growth in vivo at a more permissive drug delivery schedule than chloroquine. 
These data suggest that inhibiting autophagy may be a relevant target in fibrosarcoma 
and UPS patients, and warrant further study.     
	
Results: 
 
Increased Sensitivity to Autophagy Inhibition Under Stress Conditions in Fibrosarcoma 
and UPS cells 
 
Initially, we assessed whether autophagy was important for STS cell survival 
under stress conditions. Using chloroquine (CLQ), a well-established inhibitor of 
autophagy63, we assessed whether HT-1080 fibrosarcoma cells and KIA and KP 
undifferentiated pleomorphic sarcoma cells24,83 were sensitive to autophagy inhibition. 
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While all three cell lines had varying IC50 when treated with chloroquine under replete 
and normoxic conditions, hypoxic (1% O2) and low serum and glucose (1% FBS, 1 mM 
glucose) conditions increased their sensitivity to chloroquine (Fig. 26a – 26c). 
Combining these stresses to mimic ischemia, these STS cells showed even greater 
sensitivity to autophagy inhibition (Fig. 26d).  
We next assessed whether chloroquine treatment would affect cell proliferation 
under similar growth conditions. HT-1080 cells under replete and normoxic conditions 
showed decreased cell growth only under high doses of chloroquine (100 µM) (Fig. 
27a). However, under either 1% O2, low serum and glucose conditions, or both, 
chloroquine inhibited HT-1080 growth at even 25 µM concentration (27b – 27d). These 
findings were also recapitulated in KP cells as well (data not shown). To confirm that 
these results were not due to off-target effects of chloroquine, we repeated the HT-1080 
proliferation assay using an independent autophagy inhibitor, Bafilomycin A64. At 
nanomolar concentrations, Bafilomycin A treatment mimicked chloroquine treatment in 
HT-1080 cells, reducing cell growth at lower drug concentrations under stress conditions 
(Fig. 27e – 27h) 
To additionally confirm that chloroquine was inhibiting autophagic processes in 
our STS cells, we analyzed protein levels of the autophagy readouts p62 and LC3 in HT-
1080, KP and KIA cells. Consistent with autophagy inhibition, chloroquine treatment 
increased p62 abundance, as well as the phosphatidylethanolamine-conjugated form of 
LC3, LC3-II 116(Fig. 28a). Furthermore, in HT-1080 cells expressing an LC3-GFP 
construct117, chloroquine treatment increased LC3 punctae size in cells under replete 
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Figure 26: Fibrosarcoma and UPS cells show heightened sensitivity to the autophagy inhibitor chloro-
quine under hypoxic and ischemic-like stress. Cytotoxicity curves of a. HT-1080 fibrosarcoma cells, b. KIA 
UPS cells, and c. KP UPS cells treated with chloroquine at the indicated doses. Cells were grown under 
normoxic (21% O2) or hypoxic (1% O2) conditions, with repleate (10% FBS, 25 mM glucose) or Low Serum/-
Gluc. (1% FBS, 1 mM glucose) media. d. Quantification of IC50 experiments of HT-1080, KIA, and KP cells 
treated with chloroquine from a - c. Each bar represents two independent experiments performed with 8 
biological replicates per condition. 
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Figure 27: Autophagic inhibition reduces HT-1080 proliferation, and this effect is enhanced under 
hypoxic or ischemic-like conditions in vitro. a. - d. Relative cell counts of HT-1080 fibrosarcoma cells 
treated with PBS control or chloroquine (CLQ) at the indicated concentrations. Cells were grown under a. 
normoxic (21% O2) and replete media conditions (10% FBS, 25 mM glucose), b. hypoxic (1% O2) and replete 
media conditions, c. normoxic and low serum/glucose conditions (1% FBS, 1mM glucose), d. hypoxic and low 
serum/glucose conditions. e. - h. Relative cell counts of HT-1080 cells treated with DMSO control or bafilomy-
cin A (Baf. A) at the indicated concentrations under similar growth conditions as a. - d.. Each bar represents 
two independent experiments performed with four biological replicates per condition. 
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conditions (Fig. 28b), and punctae sizes was also enhanced upon either oxygen or 
serum/glucose depravation (Fig. 28b – 28c). LC3 punctae were similarly larger upon 
bafilomycin A treatment, however there was no further significant increase in punctae 
size upon low serum/glucose depravation. (Fig. 28d). Together, these data suggest that 
soft tissue sarcoma cells are further sensitized to chemical inhibitors blocking autophagy 
under tumor-like stresses of low oxygen and nutrient availability. 
 
ATG7 Knockdown phenocopies pharmacologic inhibition of autophagy in fibrosarcoma 
cells  
  
Since autophagy inhibitors have side effects that may impact cellular processes 
outside of the autophagic pathway, we next decided to directly inhibit processes involved 
in autophagy. We employed shRNAs targeting ATG7 mRNA, which encodes a protein 
that has a pivotal role in the conjugation of LC3 to phosphatidylethanolamine through the 
ATG5-ATG12 complex118,119. ATG7 shRNA achieved robust knockdown at both the 
mRNA and protein level in HT-1080 cells (Fig. 29a). Knockdown of ATG7 in HT-1080 
cells increased p62 protein accumulation, as well as reduced overall LC3 expression 
(Fig. 29a) Under hypoxic and ischemic-like stress conditions (similar to the conditions in 
Fig. 27a – 27d), HT-1080 cells lacking ATG7 showed increased cell death, as 
demonstrated by Annexin/PI staining (FIG 29b). Taken together, ATG7 knockdown in 
fibrosarcoma cells recapitulated the phenotype of the pharmacologic inhibitors 
chloroquine and bafilomycin A, suggesting that the phenotypes observed are through 
autophagic inhibition, as opposed to off target effects. 
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Figure 28: Stress conditions increase autophagic flux in STS cells in vitro, and pharmacologic inhibi-
tion effectively target this pathway. a. Immunoblot of KIA, KP, and HT-1080 cells grown for 16 hours under 
21% or 1% O2, in the presence or absence of chloroquine (25 μM, 6 hours of treatment) for autophagic mark-
ers p62 and LC3I/II. b. Measurement of average LC3 punctae size in HT-1080 cells expressing an LC3-GFP 
construct, grown under 21% or 1% O2, in the presence or absence of chloroquine (25 μM) under replete media 
or c. low serum/glucose conditions for 16 hours. Each bar represents the average of two independent experi-
ments performed in triplicate. Representative images are shown on the right. d. Quantification of LC3-GFP 
punctae size in HT-1080 cells under replete and low serum/glucose conditions, grown under 21% or 1% O2, in 
the presence or absence of bafilomycin A (100 nM) for 16 hours. Each bar represents two independent experi-
ments performed in triplicate. * = P < 0.05. ** = P < 0.01. *** = P < 0.001.
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Figure 29: ATG7 knockdown in fibrosarcoma cells decreases cell viability under hypoxic and isch-
emic-like stress. a. Left: mRNA expression of ATG7 in HT-1080 fibrosarcoma cells expresing scrambled 
(SCR) control or ATG7 targeted shRNA. Each bar represents biological duplicates. Right: Immunoblot of ATG7 
and autophagy readouts p62 and LC3 in HT-1080 cells expressing SCR or ATG7 7 shRNA. Cells were grown 
under normoxic (21% O2) or hypoxic (1% O2) conditions, with repleate (10% FBS, 25 mM glucose) or Low 
Serum/Gluc. (1% FBS, 1 mM glucose) media for 16 hours. b. Quantification of annexin/PI staining of HT-1080 
cells expressing SCR or ATG7 shRNA. Cells were grown under normoxic (21% O2) or hypoxic (1% O2) condi-
tions, with repleate (10% FBS, 25 mM glucose) or Low Serum/Gluc. (1% FBS, 1 mM glucose) media for 16 
hours. Each bar represents two independent experiments performed with 3 biological replicates per condition. 
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Loss of HIF-1α enhances sensitivity to autophagy inhibition 
 
 We next wished to define HIF-1α’s role in autophagy in STS, and whether HIF-1α 
affects the sensitivity of cells to autophagic inhibitors. We first determined if BNIP3L, a 
hypoxically induced pro-autophagic protein which was overexpressed in hypoxic STS 
patient samples6,66, was regulated by HIF-1α in UPS cells. Indeed, when KIA UPS cells 
were grown under 1% O2 conditions, BNIP3L protein levels were upregulated (Fig. 30a), 
and upon shRNA mediated knockdown of HIF-1α, BNIP3L levels were reduced under 
1% O2. BNIP3L abundance was not affected by 25 µM chloroquine treatment, however 
we noticed HIF-1α protein accumulation under 21% O2 conditions (Fig. 30a, discussed 
further below). Since HIF-1α may promote autophagy through BNIP3L, we next 
determined if knockdown of HIF-1α would further sensitize STS cells to autophagic 
inhibition. Under 21% O2, KIA and KP cells with or without HIF-1α had similar IC50 
values to chloroquine (Fig. 30b). However, under 1% O2, HIF-1α deficient cells are more 
sensitive to chloroquine treatment than scrambled shRNA control cells (Fig. 30b).  
 Given our result that chloroquine treatment elevated HIF-1α protein levels under 
normoxic conditions, we next wanted to assess if HIF-1α was activating downstream 
effector genes, and by what mechanism HIF-1α was being stabilized under these 
conditions. Previous studies have suggested that chloroquine treatment increases 
reactive oxygen species (ROS) levels in cells120, and in other cell contexts, chloroquine 
treatment has been shown to increase HIF-1α levels121. Since elevated ROS levels are 
able to stabilize HIF-1α122, we tested whether antioxidant treatment (N-acetylcystine,  
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Figure 30: Loss of HIF-1α sensitizes STS cells to autophagic inhibition. a. Immunoblot of HIF-1α and 
BNIP3L in KIA UPS cells infected with lentivirus expressing scrambled control shRNA or HIF-1α shRNA. Cells 
were treated with PBS or 25 μM of chlroquine (CLQ) for 16 hours, as well as grown in 21% or 1% O2 for 16 
hours. b. Cytotoxicity assay of KIA and KP cells expressing scrambled (SCR) or HIF-1α (HIF1a) shRNA 
treated with chloroquine at the indicated doses. Cells were grown under normoxic (21% O2) or hypoxic (1% 
O2) conditions, with repleate (10% FBS, 25 mM glucose) or Low Serum/Gluc. (1% FBS, 1 mM glucose) media. 
Each data point represents 4 biological replicates.  
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Figure 31: Chloroquine increases HIF-1α accumulation through increased ROS, but does not promote 
HIF-1α target gene expression. a. Immunoblot of HIF-1α in HT-1080 fibrosarcoma cells treated with PBS or 
25 μM of chlroquine (CLQ), and 0.5 - 2 mM N-acetylcystine (NAC) for 16 hours. Cells were grown under 21% 
or 0.5% O2 for 16 hours. b. mRNA expression of HIF-1α target genes Ldha and Pgk1 in KIA cells treated with 
PBS control or 25 μM chloroquine, with or without 2 mM NAC for 16 hours. Cells were grown under normoxic 
(21% O2) or hypoxic (0.5% O2) conditions for 6 hours.  
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NAC) could reverse HIF-1α stabilization with chloroquine. Upon chloroquine treatment, 
we again observed HIF-1α stabilization in another cell line (HT-1080 cells) under 21% 
O2. However, this increase was at a much lower level than PBS treated cells under 1% 
O2 (Fig. 31a). The addition of 0.5 – 2 mM NAC in chloroquine treated cells reversed the 
buildup of HIF-1α under 21% O2, but similar NAC treatment did not affect HIF-1α 
accumulation under 1% O2 (Fig. 31a). Furthermore, HIF-1α target genes Ldha and Pgk1 
were not elevated in chloroquine treated KIA cells under normoxic or hypoxic conditions 
for 6 hours (Fig. 31b). Collectively, these data suggest that under normoxic settings, 
chloroquine increases HIF-1α expression due to increased ROS levels, but HIF-1α 
cannot promote the transcription of its target genes.  
 
Inhibition	of	autophagy	with	chloroquine	reduces	STS	growth	in	vivo	
We next assessed if chloroquine is an effective treatment in slowing UPS growth 
in vivo. Once UPS allografts of KIA cells reached approximately 100 mm3, mice were 
treated with PBS control or chloroquine at 60 mg/kg/day115. Chloroquine significantly 
inhibited KIA tumor growth (Fig. 32a), as well as reduced tumor weights at time of 
sacrifice (Fig. 32b). To determine if autophagy was inhibited in KIA tumors in the 
chloroquine treated mice, we measured p62 protein levels and found increased p62 
expression in chloroquine treated compared to PBS treated animals (Fig 32c).  
We established whether the tumor growth difference was due to increased 
apoptosis, decreased proliferation or both. Expression of cleaved-caspase-3, a marker   
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Figure 32: Chloroquine inhibits autophagy and growth of KIA tumors in vivo a. Tumor sizes of KIA 
allografts in mice treated with PBS control (n = 10) or chloroquine (CLQ, n = 10) at 60 mg/kg/day. Tumors were 
allowed to reach ~100 mm3 before treatment was started (day 0).  * = P < 0.05. ** = P < 0.01. *** = P < 0.001. 
b. Weights of KIA tumors from PBS treated and CLQ treated mice at time of sacrifice. c. Immunoblot for p62 
from KIA tumors of mice treated with PBS or CLQ. d. Left: Immunoblot for caspase-3 and cleaved caspase 3 
in KIA tumors treated with PBS or CLQ. Right: Representative images of immunohistochemical staining of KIA 
tumors treated with PBS or CLQ for cleaved caspase-3. Scale bar = 50 μm e. Left: Quantification of Ki67+ KIA 
tumor cells in PBS (n = 5) or CLQ  (n = 5) treated mice. Right: Representative images of immunohistochemical 
staining for  Ki67+. Scale bar = 50 μm
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Figure 33: Chloroquine inhibits KP tumor growth in vivo a. Tumor sizes of KP allografts in mice treated 
with PBS control (n = 10) or chloroquine (CLQ, n = 10) at 60 mg/kg/day. Tumors were allowed to reach ~100 
mm3 before treatment was started (day 0).  * = P < 0.05. ** = P < 0.01. *** = P < 0.001. b. Left: Weights of KP 
tumors from PBS treated and CLQ treated mice at time of sacrifice. Right: Representative tumors isolated at 
the time of sacrifice from PBS treated or CLQ treated mice.
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of apoptosis, was elevated in chloroquine treated tumors at the protein level and by 
immunohistochemical staining (Fig. 32d). However, proliferation, as marked by Ki67+ 
cells, was not significantly different between PBS and chloroquine treated tumors (Fig. 
32e). We also treated KP (UPS) allografts with chloroquine at the same dose as KIA 
tumor bearing mice. Similar to KIA tumors, chloroquine treatment significantly slowed KP 
tumor growth in vivo (Fig. 33a), as well as lowered tumor weights at time of sacrifice 
(Fig. 33b). These data show that inhibiting autophagy in vivo significantly reduces UPS 
tumor growth, through increasing the apoptotic rate in tumors. 
The autophagy inhibitor Lys05 potently inhibits STS growth in vitro and in vivo. 
 The chloroquine derivative hydroxychloroquine has been investigated in 
combination with other cancer therapeutics in a number of clinical trials in multiple 
different cancer subtypes123. However, due to dose-limiting toxicity of this drug, it has 
been difficult to achieve consistent autophagic inhibition in patients’ tumors, at least in 
the drug combinations analyzed. Therefore, new autophagy inhibitors more potent than 
chloroquine are under development. One such inhibitor currently under investigation is 
Lys05115. We first assessed Lys05’s IC50 in our STS cell lines in vitro. Lys05 had a lower 
IC50 than chloroquine (Fig. 34a – 34c) in HT-1080, KIA, and KP cell lines in all four 
growth conditions tested (compare to Fig. 26a – 26c). In particular, under ischemic-like 
conditions, the Lys05 IC50 was greatly reduced to 0.9 nM, 0.22 nM, and 0.15 nM in HT-
1080, KIA, and KP cells respectively. 
	    Next, we assessed whether Lys05 was effective in vivo in fibrosarcoma and 
UPS cells. Following a previously established dosing schedule115, we treated mice	
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Figure 34: Fibrosarcoma and UPS cells are highly sensitive to the autophagy inhibitor Lys05 under 
hypoxic and ischemic-like stress. Cytotoxicity curves of a. HT-1080 fibrosarcoma cells, b. KIA UPS cells, 
and c. KP UPS cells treated with Lys05 at the indicated doses. Cells were grown under normoxic (21% O2) or 
hypoxic (1% O2) conditions, with repleate (10% FBS, 25 mM glucose) or Low Serum/Gluc. (1% FBS, 1 mM 
glucose) media. d. Quantification of IC50 experiments of HT-1080, KIA, and KP cells treated with chloroquine 
from a - c. Each bar represents two independent experiments performed with 8 biological replicates per condi-
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a
Figure 35: Fibrosarcoma and UPS tumor growth is inhibited by Lys05 in vivo. a. Sizes of HT-1080 
fibrosarcoma xenografts, treated with PBS (n = 4) or Lys05 (60 mg/kg, n = 6) on the days indicated by arrow-
heads. Mice received no treatment on days without arrowheads. ** = P < 0.01. *** = P < 0.001. b. HT-1080 
tumor weights at time of sacrifice in mice receiving PBS or Lys05. * = P < 0.05. c. Weights of PBS and Lys05 
treated mice pre-treatment and at the time of sacrifice. d. Tumor sizes of KP and KIA allografts treated with 
PBS (n = 10 for each cell line) or Lys05 (60 mg/kg, n = 10 for each cell line). Mice received PBS or Lys05 on 
days indicated by arrowheads. **** = P < 0.0001. e. Tumor weights of PBS or Lys05 treated KP and KIA 
allografts at time of sacrifice.
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with 60 mg/kg of Lys05 (similar to chloroquine) for three consecutive days, followed by a 
two day drug holiday. HT-1080 xenograft tumor size was significantly inhibited in Lys05 
treated mice (Fig. 35a). At sacrifice, the tumor weights of mice receiving Lys05 was 0.15 
grams, compared to 0.28 grams in the PBS control treated mice (Fig. 35b). In addition, 
there was no significant weight change over the treatment course in mice receiving 
either PBS or Lys05 (Fig. 34c). Similarly, in mice bearing KIA and KP allografts, Lys05 
treatment with the same dosing schedule significantly reduced tumor growth (Fig. 35d) 
and tumor weights (Fig. 35e). Collectively, these data suggest that autophagic inhibition 
with Lys05 can significantly reduce fibrosarcoma and UPS growth in vivo even when 
administered in a more permissive schedule than chloroquine. 
 
Discussion: 
 
 Given the low response rates to standard of care chemotherapeutics in 
unresectable and metastatic soft tissue sarcoma71,72, there is a pressing need for new 
therapeutic regimens in treating this aggressive disease. Newer targeted therapeutics 
are currently being evaluated102,124, and by using a rational approach with these drugs to 
inhibit the precise molecular processes driving specific STS subtypes, better patient 
outcomes will hopefully be achieved. In sarcomas, several preclinical studies have 
identified specific subtypes that respond to autophagic inhibition, often in combination 
with other targeted therapeutics67,68.  
In this study, we show that fibrosarcoma and UPS cells are sensitive to 
chloroquine treatment as a monotherapeutic in vitro, and this sensitivity is enhanced 
under conditions of hypoxia (1% O2) and ischemic-like stress (reduced serum and 
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glucose concentrations in the growth media). These results were recapitulated in 
bafilomycin A treated cells, as well as with shRNA mediated ATG7 knockdown. Our data 
suggest that HIF-1α promotes autophagy in UPS cells in vitro, as loss of HIF-1α 
increased the sensitivity to chloroquine. Interestingly, we observed increases in HIF-1α 
protein levels upon chloroquine treatment under normoxic conditions in vitro, however 
downstream HIF-1α target genes were not upregulated.  
In vivo, daily treatment of mice with chloroquine bearing STS tumors showed 
significant reduction in tumor growth due to increased levels of apoptosis, without any 
gross changes in overall weight. Additionally, we tested Lys05, a more potent inhibitor of 
autophagy than chloroquine, in our STS cell lines in vitro and in vivo. We observed 
significant reduction of allograft and xenograft growth with this compound, even with a 
treatment schedule that included drug holidays. These results suggest that autophagic 
inhibition through use of Lys05 merits further clinical investigation in the STS subtypes 
analyzed herein, and may be of potential therapeutic benefit in these patient populations.  
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Chapter 4: Concluding Remarks 
 
The previous two chapters have introduced two distinct, but interconnected 
pathways that are present in several high-grade soft tissue sarcomas, the hypoxic 
response (chapter 2) and autophagy (chapter 3). In chapter 2, I showed that EPAS1 
expression was lost in human STS samples, and that knockdown or loss of HIF-2α 
accelerated the growth of UPS, fibrosarcoma, and dedifferentiated liposarcoma in vivo. 
In both UPS and liposarcoma, I demonstrated that loss of HIF-2α increased mTORC1 
signaling. In UPS, HIF-2α deficient tumors showed increased ANO1 accumulation, which 
increased CAMKII phosphorylation and in turn promoted mTORC1 activation. 
Additionally, I established that EPAS1 could be re-expressed through epigenetic 
modifying agents. Specifically, class I and II HDAC inhibitors like SAHA (Vorinostat) 
increased HIF-2α, but not HIF-1α, expression. SAHA inhibited STS growth as a 
monotherapeutic, both in vitro as well as in vivo. Interestingly, I showed that SAHA’s 
anti-tumor effect in STS was predominantly due to HIF-2α being re-expressed, as 
knockdown or deletion of HIF-2α prevented SAHA from affecting tumor growth. In 
chapter 3, I demonstrated that autophagy plays an important role in STS survival under 
stress conditions. Under ischemic-like conditions, fibrosarcoma and UPS cells show 
increased sensitivity to pharmacologic inhibition of autophagy, which was recapitulated 
with ATG7 knockdown. Also, HIF-1α loss increased sensitivity to autophagic inhibition in 
vitro. I confirmed that autophagic inhibition with chlorquine reduced fibrosarcoma and 
UPS tumor growth in vivo, and a more potent autophagic inhibitor, Lys05, demonstrated 
similar effects but with fewer drug treatments over the time course analyzed. Taken 
together, these studies add to our understanding of the progression of mesenchymal 
tumors, and illustrate potentially new therapeutic options for patients with this disease. 
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Here, I will address some of the broader implications that arise from this body of work, 
as well as suggest future studies to build upon these ideas. 
Hypoxic responses in STS 
 Hypoxia is a common feature in several STS4, and is associated with a worse 
prognosis in patients. Therefore, understanding how hypoxia, its cellular sensors HIFs, 
and downstream effectors work is important in this tumor context. Clinically, 
understanding each HIFα’s effect in different cancer contexts is important, as the 
development of hypoxia-induced drugs125 and HIF inhibitors80,126 continues. While we 
and others have demonstrated that HIF-1α and HIF-2α can have different, if not opposite 
roles in distinct cancers such as clear cell renal cell carcinoma21 (ccRCC) and non-small 
cell lung cancer23, the data presented in chapter 2 of this dissertation comprises the first 
attempt of characterizing HIF-2α’s role in STS and demonstrating that it opposes STS 
growth in the subtypes examined. However, the majority of HIF inhibiting compounds are 
not completely selective for one specific isoform. These inhibitors range in their specific 
mechanisms of action. For example, some HIF inhibitors block transcriptional activity 
and DNA binding through inhibiting dimerization of HIFα with ARNT127, or by inhibiting 
p300 recruitment128. Other HIF inhibiting drugs indirectly affect HIF-1α translation, often 
through pathways that impinge on the HIF pathway (i.e. blocking mTOR129 or 
EGFR/PI3K pathway130). Therefore, a complete understanding of both HIFα’s role in a 
specific cancer is essential before these pan-HIFα inhibiting compounds are tested 
clinically.  
 However, a HIF-2α specific inhibitor was recently developed as a potential 
therapeutic in ccRCC79, a malignancy where HIF-2α is pro-tumorigenic131. This 
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compound specifically binds to a hydrophilic cavity inside HIF-2α, disrupting the HIF-
2α/ARNT heterodimer. Importantly, the similar pocket in HIF-1α is smaller than in HIF-
2α, preventing the drug from inhibiting the HIF-1α/ARNT heterodimer79.  Recently, the 
crystal structures of both HIF-α/ARNT heterodimers have been resolved, confirming the 
location where this drug inhibits HIF-2α/ARNT binding132.  
 Now that the crystal structure of the HIF-α/ARNT heterodimers has been 
resolved, hopefully other areas of the HIF-1α/ARNT interaction can be specifically 
targeted in a similar way as HIF-2α/ARNT.  Using datasets of cancer mutations such as 
COSMIC to probe sites of HIF-1α where mutations are common, we may discover more 
specific and effective therapeutics specifically against this transcription factor. HIF-1α 
specific inhibitors could be very beneficial to STS patients, as they would prevent the 
pro-metastatic effects of HIF-1α24 without affecting the anti-growth property of HIF-2α 
described here. These inhibitors could also be tested on the variety of STS mouse 
models that exist for different subtypes.  
 Besides direct HIF inhibition, data from chapter 2 of this dissertation suggest that 
epigenetic modifying drugs may be useful in modulating HIF levels in this disease. In the 
context of the STS subtypes analyzed, our work suggests that histone deacetylation 
silences HIF-2α expression, and by therapeutically inhibiting this process with HDAC 
inhibitors, HIF-2α can be re-expressed. It would be interesting to characterize HIF-2α 
expression changes upon HDAC inhibition in different tumor contexts, especially in 
malignancies where HIF-2α has shown to be tumor suppressive22,23. Furthermore, we 
observed that longer treatment courses of the HDAC inhibitor SAHA led to resistance, 
with Epas1 expression levels not significantly increased compared to controls (Fig. 19a). 
One intriguing possibility is that the Epas1 locus is becoming epigenetically silenced 
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through a different mechanism upon HDACi treatment, such as through histone or DNA 
methylation. Combining HDACi and histone methylation/DNA methyltransferase 
inhibitors in STS and observing long-term changes in Epas1 could address this question. 
 In chapter 2, we used two separate HDAC inhibitors, SAHA and Trichostatin A, 
which both inhibit multiple class I and class II HDACs in cells87,133. It would be interesting 
to determine which HDAC(s) specifically are involved in deacetylating the EPAS1 locus 
in STS, by systematically knocking down expression of each HDAC in STS cells using a 
shRNA mediated approach. Knowing which specific HDAC is responsible for 
deacetylating EPAS1 is important, since newer HDACi are being developed that are 
more selective in which HDAC they block111.  
 An interesting result in chapter 2 that requires future study is how EPAS1 mRNA 
abundance affects HIF-2α protein levels in the STS cells analyzed. Currently, the HIFα 
subunits are thought to be mainly regulated through post-translational mechanisms (e.g. 
hydroxylation and degradation by the PHD family of enzymes)12. But, SAHA treatment 
increased mRNA expression of EPAS1 only two to five fold in STS cells, and yet an 
increase in HIF-2α protein abundance was observed. This increase in HIF-2α protein 
may potentially be due to off target effects of SAHA. Knockdown of specific HDACs with 
shRNA (as mentioned above) and observing whether there are changes in HIF-2α 
protein levels may help address this question. However, the increase in HIF-2α protein 
may also be due to increased EPAS1 transcript levels in STS cells, in which the 
translate protein levels are amplified to a point at which the normal post-translation 
regulation and degradation machinery cannot function properly. Understanding the state 
of these regulators (e.g. PHDs, FIH) in STS is important, because it may potentially offer 
	
	
77	
another druggable target in which HIF-2α protein levels can be increased in these 
malignancies.  
 Another direction of future research will be to investigate whether HIF-2α loss 
affects sarcomagenesis, and at which stage of development. Currently, there are several 
different theories as to what molecular pathways control sarcomagenesis in different 
sarcoma subtypes. For high-grade, poorly differentiated/dedifferentiated sarcomas, 
altered Wnt signaling has been one proposed as a mechanism of transformation. Some 
groups have proposed that inhibiting Wnt signaling in mesenchymal stem cells (MSC) 
can give rise to UPS134, while others show that Wnt signaling is increased in several 
different STS cell lines in vitro135. However, a lack of a relevant in vivo model in which 
sarcomagenesis can be spatially and temporally tracked has made it difficult to answer 
these questions.   
Additionally, the role of HIFs in sarcomagenesis has also not been addressed. 
Although it may seem unlikely that the HIFα’s affect the early stages of tumor initiation, 
as very hypoxic/ischemic areas likely have not developed, in certain tissues of the body 
(e.g. renal medulla, skeletal muscle), low oxygen tension can be present 
physiologically12. As demonstrated in chapter 2 of this dissertation, loss of HIF-2α in STS 
in vivo led to faster tumor growth of fibrosarcoma and dedifferentiated liposarcoma 
xenografts, as well as faster development of macroscopically visible UPS tumors in the 
autochthonous mouse model. However, since the xenografts were of already 
transformed cells, and the autochthonous tumors could only be assessed once 
macroscopically visible, the question of HIF-2α’s function during the initiating stages of 
sarcomagenesis remains unknown.  
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To help address the question of HIF-2α’s role in sarcomagenesis, we are 
currently generating an autochthonous mouse model that generates UPS tumors in 
muscle satellite cells136. These mice have the background of Pax7CreER-LSL-
KrasG12D/+Trp53fl/fl (Pax7KP) and Pax7CreER-LSL-KrasG12D/+Trp53fl/flEpas1fl/fl 
(Pax7KPH2). Upon tamoxifen treatment, Pax7KP mice should generate UPS tumors in 
approximately seven to eight weeks136. Unlike the autochthonous model described in 
chapter 2 of this dissertation, the cell of origin of the UPS tumors is specifically a Pax7+ 
muscle satellite cell. Therefore, Pax7+ muscle satellite cells can be isolated from the 
mice, and after ex vivo administration of tamoxifen, we can study any changes in 
molecular pathways in these cells. Furthermore, we are interested to observe if 
Pax7KPH2 form more tumors (or tumors more quickly) compared to Pax7KP mice. We 
will be interested in assessing if Wnt signaling affects sarcomagenesis in this model, and 
whether HIF-2α deletion alters the Wnt pathway. However, we will also attempt an 
unbiased RNA-seq based approach to determine if other pathways are altered in 
sarcomagenesis, with or without HIF-2α present. 
 Finally, although we showed in chapter 2 that loss of HIF-2α increased Ano1 
expression, the specific mechanism remains unclear. We postulated that the mechanism 
is through Myc, since loss of HIF-2α increased Myc protein levels (Fig. 11a), and ChIP-
seq data of breast and leukemia cells shows Myc binding near the ANO1 promoter. We 
hypothesize that HIF-2α loss increases Myc, because previous reports have shown that 
the HIFs promote degradation of Myc under hypoxic conditions137. Furthermore, while 
Myc targets individually were not differentially expressed in KP versus KPH2 tumors, 
overall they trended towards Myc activation (Fig. 11a). Preliminary data in KPH2 cells 
showed that treatment with 500 nM of JQ1, a potent inhibitor of the BET family of 
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bromodomain proteins that also reduces Myc expression138, reduced both Myc as well 
as Ano1 protein levels (data not shown). mRNA levels of Ano1 and Camk2a (encoding 
CAMKII) also significantly decreased upon treatment with JQ1 (data not shown). Further 
studies are necessary to prove this hypothesis, such as measuring Myc degradation rate 
in HIF-2α deficient versus HIF-2α expressing UPS cells, as well as performing ChIP of 
Myc on putative Myc binding sites in the Ano1 promoter. If Myc does in fact connect loss 
of HIF-2α promoting Ano1 expression, Myc may be another potential therapeutic target 
in this disease, and potentially other cancers where Ano1 overexpression promotes 
tumor growth96.  
Autophagy and Sarcoma 	
	 In chapter 3, I established that autophagy plays an important role in cell survival 
under stress conditions in fibrosarcoma and UPS in vitro and in vivo. Grown under in 
vitro conditions mimicking hypoxia or ischemia, the STS cell lines examined showed 
increased sensitivity to autophagy inhibition, either pharmacologically with chloroquine 
and bafilomycin A, or through knockdown of ATG7, a critical mediator of autophagy. 
Knockdown of HIF-1α increases chloroquine sensitivity in UPS cells in vitro. 
Interestingly, I noticed that chloroquine treatment stabilized HIF-1α under normoxic 
conditions in vitro, which was reversed with antioxidant treatment. However, HIF-1α did 
not activate downstream target genes under this condition. This result contrasts to 
previous reports in HeLa cells which show increased HIF-1α target gene expression 
upon bafilomycin A and chloroquine treatment139. This may be due to cell context 
differences, or that HeLa cells were treated with higher doses of autophagy inhibitors 
than were examined here. Additionally, chloroquine treatment reduced STS tumor 
growth in vivo by increasing apoptosis in STS xenograft and allografts. Finally, Lys05, a 
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newer and more potent inhibitor of autophagy than chloroquine115, also reduced STS 
tumor growth in vivo. 
 It will be important to define autophagy’s relevance to STS in patients. 
Unfortunately, thorough sarcoma clinical datasets encompassing multiple subtypes with 
expression data and patient outcome are only beginning to be compiled, such as The 
Cancer Genome Atlas. Currently, most sarcoma datasets have expression data on 
tumors without survival outcomes. Therefore, it is difficult to determine from prior data 
whether higher or lower expression of autophagic genes confers a survival advantage or 
disadvantage in fibrosarcoma or UPS patients. In addition, while BNIP3L and other 
autophagic markers may be upregulated in sarcomas, it remains to be determined if their 
expression can serve as a biomarker for sensitivity to autophagy inhibitors. 
As mentioned in chapter 3, chloroquine (or hydroxychloroquine) has been tested 
in mouse models and cancer patients as a pharmacologic inhibitor of autophagy. In pre-
clinical studies in mice, chloroquine has shown to effectively inhibit autophagy in several 
different tumor types, and reduce the tumor burden123. However, in order to reliably 
inhibit autophagy in patients, the dosage of chloroquine required is often too toxic and 
inconsistently achieved123. Therefore, more potent and/or less toxic autophagy inhibitors 
need to be developed to achieve reliable autophagic inhibition without the dose limiting 
side effects. 
 Lys05, a derivative of chloroquine with two aminoquinoline rings115, was designed 
to be a more potent autophagy inhibitor than chloroquine. Results from chapter 3 of this 
dissertation (Fig. 34a – 34c) show Lys05 has a lower IC50 in fibrosarcoma and UPS cells 
compared to chloroquine in vitro. Lys05 was also able to reduce tumor growth in vivo 
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(Fig. 35). While chloroquine was administered daily, Lys05 inhibited tumor growth with a 
two day drug holiday after 3 days of treatment. These results suggest that Lys05 is more 
potent than chloroquine, but the question remains as to whether Lys05 at these lower 
doses is actually less toxic and has fewer side effects than chloroquine. Future work will 
continue to analyze the effect of Lys05 treatment on the fibrosarcoma and UPS tumors 
we generated, and whether its effect on tumors was due to increasing apoptotic rates 
(similar to chloroquine), or reduced proliferation of tumors. Additionally, we will examine 
markers of autophagic inhibition in Lys05 tumors (e.g. LC3-II and p62 protein 
accumulation) to see if the drug was able to consistently block autophagy. In addition, 
these in vivo studies were performed in xenograft and allograft models, and may not fully 
recapitulate the complete tumor microenvironment seen in patients. Therefore, further 
studies using Lys05 in the autochthonous UPS model (KP model) are warranted. Future 
clinical trials testing Lys05 in sarcoma patients will address the toxicity profile of the 
drug, and hopefully recapitulate results from our mouse models. 
 Another potential direction of future study would be to combine autophagy 
inhibition with other therapeutics. Since it has been demonstrated that autophagy can be 
activated by stress from chemotherapeutics in several different tumor cell types140, 
combining traditional chemotherapeutics with Lys05 may augment tumor cell death. 
Indeed, in epithelial cancers such as breast141 and colon cancer142, combining 
chemotherapies with chloroquine or ATG7 knockdown increased tumor suppression. For 
the high grade STS subtypes examined in this dissertation, doxorubicin is the standard 
of care chemotherapeutic. Given the results in epithelial cancers, further studies 
combining doxorubicin and Lys05 may be warranted for STS.  
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Another potential therapeutic combination with autophagy inhibitors is using 
HDAC inhibitors, as it has been shown that HDAC inhibitors can induce autophagy in 
certain contexts143. In one subtype of sarcoma, malignant peripheral nerve sheath 
tumors, combining chloroquine with HDACi enhanced apoptotic cell death67. HDACi with 
Lys05 has yet to be tested in fibrosarcoma or UPS, but could prove to be an attractive 
therapeutic combination. 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
83	
MATERIALS AND METHODS 
 
Cell Culture: 
HT-1080 (fibrosarcoma) and HEK-293T cell lines were purchased from ATCC 
(Manassas, VA, USA). KIA, KP210, KP230, and KP250 cell lines were derived from UPS 
mouse tumors83. These high-grade neoplasms showed myofibroblastic differentiation 
and atypical nuclei, and by expression profiling matched human MFH/UPS. LPS246 was 
established from a primary dedifferentiated liposarcoma sample (confirmed with MDM2 
FISH analysis), and was provided by Dr. Dina Lev (Core Facilities, MD Anderson Cancer 
Center, Houston, TX)144. These high-grade neoplasms showed myofibroblastic 
differentiation and atypical nuclei83, and by expression profiling matched human 
MFH/UPS82. Cells were grown in DMEM (Corning), 2 mM glutamine, 100 units/ml 
penicillin, and 10% FBS (Gemini Biosystems).  
KP and KPH2 tumor cells were isolated from primary KP and KPH2 UPS tumors, 
respectively. Briefly, UPS were harvested from mice, and transferred to a cell-culture 
hood and cut into tiny pieces on a petri dish. Tumors were digested using collagenase 
(StemCell #07902, Vancouver, Canada) for 1 hour at 37o C. DMEM/F-12 (Sigma-Aldrich) 
with 2% FBS was then added, and the digested mixture was filtered through a 40-micron 
filter. Red blood cells were lysed with ACK lysis buffer (Lonza, Allendale, NJ) according 
to the manufacturer’s protocol. Cells were pelleted down, and washed with DMEM/F-12. 
Cells were cultured in DMEM (Cellgro, Manassas, VA) supplemented with 10% FBS and 
incubated at 37°C with 5% CO2 in a humidified cell-culture incubator. Cells were cultured 
at least 4 passages before being used for experiments, and Epas1 recombination status 
was detected through PCR. All cell lines were negative for mycoplasma contamination.  
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Hypoxia: 
Hypoxia (either 0.5% or 1% O2) was achieved using a Ruskinn InVivO2 400 
workstation. KP and KPH2 tumor derived cell lines were grown and maintained at 3% O2 
in a Hera Cell 240 (ThermoFisher Scientific) incubator, until experiments were performed 
on the cells at the stated oxygen levels. 
Mouse Models 
KPH2 mice were generated by crossing KP mice (LSL-KrasG12D/+Trp53fl/fl)83 and 
Epas1fl/fl mice88, and KPA mice were generated by crossing KP mice and Arntfl/fl mice145. 
KP, KPH2, and KPA mice are on a mixed 129/C57BL/6 background. Tumors were 
generated in 8 weeks or older mix of male and female KP, KPH2, and KPA mice by 
injecting adenovirus expressing Cre-recombinase (Ad-Cre) into the right hind limb 
musculature as previously described83. KP, KPH2, and KPA mice were sacrificed either 
7 weeks after Ad-Cre injection, or when tumors reached the maximal permissible size. 
Mice were injected with BrdU (Sigma-Aldrich) 30 minutes before sacrifice. For HT-1080 
xenografts, 1x106 cells were injected into both flanks of male Balb/c nu/nu mice (Charles 
River Laboratories, Wilmington, MA, USA). For KIA and KP250 allografts, 1x106 cells 
were injected into both flanks of female nu/nu mice (Charles River Laboratories). For KP 
and kPH2 allografts, 7.5x105 cells were injected into both flanks of female nu/nu mice 
(Charles River Laboratories). To generate LPS246 xenografts, 2x106 cells were injected 
into the flanks of scid/hairless (SHO) mice (Charles River Laboratories). Mice were 
injected with control tumors (Scrambled shRNA) in one flank and experimental tumors 
(HIF-2α shRNA) in the other for LPS246 and HT-1080 xenografts. Tumor size was 
measured every other day (except for cholorquine, Lys05, and SAHA studies, where 
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tumors were measured daily), and animals were euthanized after 14 – 50 days post-
tumor injection. Researchers were not blinded to the experimental groups during in vivo 
treatments. Animal well-being and comfort were monitored by certified veterinary staff. 
All mouse experiments were performed according to National Institutes of Health 
guidelines and approved by the University of Pennsylvania Institutional Animal Care and 
Use Committee. Sample size for each experiment was estimated using the formula n = 
((zα/2 σ)/E)2, with α = 0.05, and σ and E based off of initial HT-1080 xenograft 
experiments with scrambled and HIF-2α shRNA. No inclusion/exclusion criteria 
parameters were used in our studies. All tumors and animals used in experiments were 
included in data analysis. 
Immunoblotting 
Protein lysates were prepared in RIPA lysis buffer, and separated on 10% SDS-
PAGE gels by electrophoresis. Subsequently, the lysates were transferred to 
nitrocellulose membranes and probed with the following antibodies and concentrations: 
HIF-2α 1:1000 (Novus #NB100-122), caspase-3 1:1000 (Cell Signaling #9662 Danvers, 
MA, USA), GAPDH 1:2000 (Cell Signaling #2118), phospho-4E-BP1 1:1000 (S65, 
#9451), 4E-BP1 1:1000 (Cell Signaling #9452), phospho-S6K1 1:1000 (T389, Cell 
Signaling #9205), S6K1 1:1000 (Cell Signaling #2708), phospho-AKT 1:1000 (S473, Cell 
Signaling #9271), AKT 1:1000 (Cell Signaling #9272), ANO1 1:500 (Abcam ab64085), 
phospho-CAMKIIα 1:1000 (T286, Cell Signaling #12716), CAMKII 1:1000 (Cell Signaling 
#11945) ATG7 1:1000 (Sigma-Aldrich #A2856) BNIP3L 1:1000 (R&D Diagnostics 
AF4030) LC3 1:4000 (Cell Signaling #2775) p62 1:1000 (MBLI #PM045), β-tubulin 
1:1500 (Cell Signaling #2146). 
	
	
86	
Quantitative Real-Time PCR (qRT-PCR) 
 Total RNA was isolated from cells using the TRIzol reagent protocol (Invitrogen) 
and from tumors and skeletal muscle tissue using the RNAeasy minikit (Qiagen). RNA 
was reverse transcribed using the High-Capacity RNA-to-cDNA kit (Applied Biosystems), 
and transcript expression was determined by quantitative PCR using the Applied 
Biosystems Viia7 system. Target cDNA levels were measured with Taq-Man 
primer/probe sets (Applied Biosystems) for the following mouse and/or human targets: 
EPAS1, HIF1A, SERPINE1, MYC, CCND1, CCND2, MCM5, CDKN1A, LDHA, PGK1, 
ATG7.   Expression levels were normalized to HPRT and ACTB for each sample. 
Immunohistochemistry and immunofluorescence 
 For chapter 2, immunohistochemistry and immunofluorescence were performed 
on 5-µm paraffin embedded tissue sections. For immunohistochemistry, enzymatic 
Avidin-Biotin Complex-diaminobenzidine staining (Vector Labs) was used with 
hematoxylin used for counterstaining nuclei according to standard protocols. 
Immunohistochemistry was performed on soft tissue sarcoma and normal arterial and 
skeletal muscle tissue array (US Biomax, Rockville, MD, USA #SO801a). The following 
primary antibodies and concentrations were used for immunohistochemistry: anti-BrdU 
1:40 (Abcam #ab6326), anti-cleaved caspase-3 Asp 175 1:300 (Cell Signaling #9661) 
anti-Ki67 1:100 (Abcam #ab15580), anti-phospho-S6 (S235/236, Cell Signaling #4858), 
anti-HIF-2α (ThermoPierce #PA1-16510). The following primary antibodies and 
concentrations were used for immunofluorescence: anti-CD31 1:50 (Abcam #ab28364), 
anti-pimonidazole FITC 1:100 (Hypoxyproble HP2). Mounting media with DAPI (Life 
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Technologies #P36935) was applied last. Sections were imaged using a Leica DMRB 
microscope and an Olympus DP72 camera. 
 For chapter 3, stably transfected HT-1080 LC3-GFP cells, maintained in media 
with puromycin, were grown on pre-collagen treated slide covers and exposed to drug or 
PBS for 6 hours. At the end of the 6 hours the cells were treated with 3% 
paraformaldehyde and DAPI. The slide covers were than mounted onto a microscope 
slide and treated with Prolong Gold Antifade Reagent (ThermoFisher Scientific).  Cells 
were imaged using a Leica DMRB microscope and an Olympus DP72 camera. 
Proliferation Assay 
For chapter 2, cells were plated in triplicate for each data point, and incubated 
overnight in tissue culture dishes. The following day, DMSO or SAHA, diluted in growth 
media, was added to the cells, and the cells were place either in normoxic conditions 
(21% O2) or hypoxic conditions (1% O2). Media with drug was changed every two days. 
Cells were trypsinized, resuspended in PBS, and counted using a hemocytometer on the 
days indicated. 
For chapter 3, cells were plated in triplicate for each data point, and incubated 
overnight in tissue culture dishes. The following day, PBS or drug (CLQ, Bafilomycin A1, 
or Lys05), diluted in growth media, was added to the cells at the indicated 
concentrations. Then, the cells were place either in normoxic conditions (21% O2) or 
hypoxic conditions (1% O2). Media with drug was changed every two days. Cells were 
treated with WST-1 cell proliferation reagent (Sigma-Aldrich) and quantified using a plate 
reader following the manufacturer’s protocol at 450 nm at the end of the experiment. 
Migration Assay 
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Migration assays were performed using 24-well chambers with inserts (8-µm pores) (BD 
Biosciences). Medium containing 10% serum was placed in the lower chamber, and 
tumor cells (1 × 105) suspended in medium without serum were added to the top 
chamber. The plates were incubated under 21% or 1% O2 for 16 hours. After migration, 
nonmigratory cells were removed from the top of the insert membrane using cotton 
swabs. The underside of each membrane was fixed in Methanol and stained with DAPI 
(Invitrogen), and the number of cells that migrated completely through the 8-µm pore 
was determined in 10 random high-power fields (20x objective) for each membrane. 
Cytotoxicity Assay 
Cytotoxicity Assays 5×104 cells in 200 uL of media were plated in each of 80 wells of a 
96 well plate on the day prior to drug exposure. Cells were exposed to serial 
concentrations of chloroquine (Sigma-Aldrich), or Lys05 in complete media under 21% 
O2 or low serum (1% FBS)/low glucose (1mM) DMEM media under 1% O2. The media 
was exchanged for drug-free complete or equilibrated SG media following 24 hours of 
incubation. The media was again exchanged for complete media at 48 hours of 
incubation. Following 72 hours of incubation, cellular viability was measured using the 
CytoScan WST-1 Assay (G-Biosciences, St. Louis, MO). Spectrophotometric measures 
of absorbance were made using a SpectraMax M2e microplate reader (Molecular 
Devices, Sunnyvale, CA). 
Chromatin Immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) assays were performed using QuickChIP 
assay kits (Novus Biologicals). Briefly, five million KP250, KP, or KPH2 cells grown at 
the indicated oxygen level were fixed in 1% formaldehyde for 10 minutes at 37oC, and 
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the reaction stopped by glycine. Cells were washed, collected, and lysed using SDS 
buffer containing protease inhibitor cocktail, and then sonicated into DNA fragments of 
300-800 bp in size. Supernatants were diluted and pre-cleared with salmon sperm 
DNA/protein A/G agarose, and a 10 µl aliquot was saved for input control. The rest of the 
sample was immunoprecipitated with 5 ug of the following antibodies overnight: Rabbit 
IgG (Cell Signaling), Histone H3 (Abcam), Histone H3 Acetyl K9+K14+K18+K23+K27 
(Abcam). Antibody-nucleoprotein complexes were recovered by incubating 60 uL of 
salmon sperm DNA/protein A/G agarose for 1 hour at 4oC with rotation. Beads were 
washed and antibody-nucleoprotein complexes were eluted from protein A/G agarose 
beads in elution buffer, de-crosslinked by adding 20µL 5M NaCl and incubated at 65oC. 
Subsequently, RNAase A and proteinase K were added, and DNA fragments were 
purified using QIAquick PCR purification kit (Qiagen).  Semi-quantitative PCR was 
performed with the following primers: Epas1 Forward: 5’-
CATTACTCAGTCCTGCGCTAACTG-3’; Epas1 Reverse: 5’-
CTCAGGACACTGCCGAGGATTGTA-3’;  Hif1a Forward: 5’-
AATCACTTGGAGACTTCCCTTGTT-3’; Hif1a Reverse: 
5’CACGTTGCTCTCAGCCAATCAGGA-3’. 
Oncomine Study Design 
We used publically available databases through Oncomine Research Premium 
edition software (version 4.5, Life Technologies) to query HIF-2α expression and survival 
data in sarcomas relevant to our study. For expression data, we used the Barretina et. 
al.89 and Gobble et. al.90 datasets, and for survival data the Gobble et. al. dataset was 
analyzed. 
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Survival Analysis 
Available patient survival data was obtained from Gobble et al. dataset for 
liposarcoma patients through Oncomine. Patients were divided into 2 groups: tumors 
expressing the highest 50% of EPAS1 ‘High EPAS1’ and lowest 50% ‘Low EPAS1’, and 
Kaplan-Meier survival analyses were performed for overall survival of patients. 
CT Imaging 
Computer tomography (CT) images were generated using an Imtek MicroCAT II 
microCT scanner.  The settings for the scan were 80 kVp, 500 uA with a 375 ms 
exposure time per projection. 360 projections were taken for the scan lasting 
approximately 6 minutes. Reconstruction was performed with the software provided with 
the scanner: MicroCAT: Image Reconstruction, Visualization, & Analysis. It used a 
Feldkamp Reconstruction with a Shepp-Logan Filter. Voxel size is 103 µm x103 µm x 
103 µm. Tumor volume was measured from scans using Amide software, and 
measurements were confirmed by a board-certified radiologist who was blinded to the 
treatment given to each mouse. 
RNA-seq 
RNA was extracted from KP and KPH2 FFPE tumor sections using RNeasy 
FFPE kit (Qiagen #73504). Library preps and RNA-seq were performed by the Next 
Generation Sequencing Core at the University of Pennsylvania, using TruSeq Stranded 
Kit (Illumina #RS-122-2201), Ribo-Zero Gold Kit (Epicentre #MRZG126) and an HiSeq 
100SR (Illumina). Raw sequence and quality files were aligned to the mouse genome 
(GRCm38) using the RNA alignment tool STAR (version 2.4, 
https://code.google.com/p/rna-star/). Unique transcript alignments were counted for each 
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sample using htseq-count (version 0.6.1, http://www-
huber.embl.de/users/anders/HTSeq/doc/count.html) against the RefSeq transcripts for 
GRCm38, yielding counts for 26,667 transcripts for each sample. Principle Components 
Analysis of raw count data revealed that one HIF-2α knockout sample was a technical 
outlier. This sample was excluded from statistical analysis. 
Differential expression and gene set enrichment analysis 
Transcript count files for 3 HIF-2α knockout samples and 4 wild type samples 
were analyzed with DESeq2 (version 1.6, 
http://bioconductor.org/packages/release/bioc/html/DESeq2.html) for differential 
expression. Log2-transformed, normalized intensities were also exported from DESeq2 
for visualization and used as input for Gene Set Enrichment Analysis (see below). 
Overall sample relatedness was visualized with Principal Components Analysis (PCA, as 
implemented in Partek Genomics Suite v6.6, Partek, Inc. St. Louis, MO) using the 
normalized expression intensities for all transcripts. Log2-transformed expression 
intensities from these samples were imported into GSEA (version 2.1, 
http://www.broadinstitute.org/gsea/index.jsp). Enrichment of gene sets corresponding to 
Canonical Pathways (C2-CP from the Molecular Signatures Database v4.0, 
http://www.broadinstitute.org/gsea/msigdb/index.jsp) was tested with default settings. 
Tables of enriched pathways for genes up in HIF-2α knockout or wild type were 
exported, with a FDR < 0.1 cutoff. 
TCGA	Bioinformatics	Analysis	
Level 3 data comprising regions with altered copy number and methylation status 
in sarcoma were downloaded through the TCGA portal (https://tcga-
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data.nci.nih.gov/tcga/tcgaHome2.jsp). Data was analyzed with Partek software (version 
6.6). Tumor samples for copy number analysis consisted of 260 primary tumors, 3 
recurrent tumors, and 1 metastatic tumor. The results from blood and normal controls 
were eliminated from the analysis as they contained no amplifications or deletions. 
Briefly, sample files were lined up and concatenated. Thresholds for amplifications and 
deletions were set at 0.55 and -0.4, as based on previously published literature. 
Methylation analysis was performed on 242 primary tumors, 2 recurrent tumors, 1 
metastatic tumor, and 4 normal tissues. Probes annotated for proximity to EPAS1 were 
evaluated. All probes were tested for differential beta values between normal and all 
tumor samples with ANOVA followed by Benjamini-Hochberg FDR correction. 
Ingenuity	Pathway	Analysis	
DESeq2 statistical results for differential expression were uploaded to Ingenuity 
Pathway Analysis. Genes with at least a 0.75 log2 ratio (+/- 1.7 fold) and a false 
discovery rate corrected p-value of < 0.05 were analyzed. The changes in the subset of 
these genes that were known to interact with mTOR were used to predict the activity 
changes of MTOR in KPH2 versus KP tumors. Canonical pathway analysis was also 
performed, with the top 15 most statistically significant pathways shown (orange bars = 
pathway predicted to be more active in KPH2 tumors, blue bars = pathway predicted to 
be less active in KPH2 tumors, grey bar = no activity pattern available). 
Statistical Analysis 
Statistical analysis was performed using Prism (GraphPad Software). Data are 
shown as mean + s.e.m. unless otherwise specified. Data were reported as biological 
replicates, with technical replicates indicated in figure legends. Unpaired two-tailed 
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student t-tests were performed to determine if results were statistically significantly 
different, with a p-value cutoff less than 0.05 considered significant. Variation within each 
data group was measured with Graphpad Prism software, and found to be similar 
between groups tested. 
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